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Abstract 
Cataract	is	an	opacification	of	the	eye’s	lens.	It	is	the	leading	cause	of	blindness	and	causes	life-impacting	vision	loss	for	millions	of	people	worldwide.	Currently	the	only	treatment	 is	 surgical	 implantation	 of	 an	 intra-ocular	 lens.	 Due	 to	 the	 number	 of	annual	 surgeries	 this	 approach	 is	 expensive	 and	 can	 result	 in	 a	 range	 of	 sight-affecting	complications.	Difficulties	arise	 in	accessing	vision-restoring	surgery	 for	people	 with	 cataract	 living	 in	 developing	 countries	 due	 to	 inadequate	 access	 to	cataract	 surgery.	 Greater	 understanding	 of	 cataract	 molecular	 mechanisms	 is	required	for	development	of	anti-cataract	drugs	that	may	be	easier	to	access	than	surgery.	Several	cataract	risk	factors	have	been	postulated;	however,	their	specific	molecular	 mechanisms	 are	 poorly	 identified.	 This	 is	 due	 largely	 to	 a	 lack	 of	functional	human	lens	tissue	available	for	studying	cataract.	Previous	investigations	of	 cataract	 have	 used	 animal	 models	 to	 study	 lens	 development	 and	 cataract;	however,	 there	 are	 significant	 differences	 between	 humans	 and	 animal	 lenses	including	protein	expression	and	cell	membrane	composition.	Human	pluripotent	stem	(PS)	 cells	 are	a	potential	 source	of	human	 lens	 cells	 and	an	elegant	3-stage	protocol	 for	 generating	 lens	 cells	 and	 rudimentary	 lens	 tissue	 was	 published	 in	2010.	Several	groups	have	attempted	to	refine	this	protocol	with	varying	success.	Nevertheless,	all	of	these	approaches	suffer	from	three	main	issues:	i)	production	of	heterogeneous	 cultures	 of	 human	 lens	 and	 non-lens	 cells;	 ii)	 poorly-	 or	uncontrolled-production/loss	 of	 rudimentary	 lens	 tissue;	 and	 iii)	 limited	 or	 no	evidence	 that	 the	 stem	 cell-derived	 lens	 tissues	 have	 focusing	 ability	 (a	 defining	property	of	the	lens).	Very	recent	work	in	our	laboratory	overcame	the	first	of	these	issues,	allowing	simple	and	large-scale	production	of	purified,	ROR1-positive	human	lens	epithelial	cells	(LECs)	from	heterogeneous	cell	cultures	generated	from	PS	cells.	This	 ROR1+	 LEC	 purification	 protocol	 provided	 a	 starting	 point	 for	 this	 thesis	 to	investigate	conditions	for	generating	light-focusing	human	lens	tissue	in	vitro.	
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The	studies	presented	here	resulted	in	a	method	to	produce	tens-of-thousands	of	uniform,	 transparent	 and	 light-focusing	 human	 PS	 cell-derived	 lens	 organoids,	termed	micro-lenses.	These	micro-lenses	appear	able	to	model	a	clinically-relevant	cataract	 associated	 with	 exposure	 to	 the	 cystic	 fibrosis	 drug	 Vx-770.	 These	functional	 human	 micro-lenses	 represent	 a	 useful	 tool	 for	 drug	 discovery	 and	toxicity.	In	 addition	 to	 the	 successes	 of	 producing	 the	 world-first	 human	 PS	 cell-derived	micro-lenses,	 there	 were	 several	 lessons	 learned	 during	 this	 project.	 Repeated	failures	of	the	cells	to	survive	and	proliferate	on	RGDS-chitosan	film	negated	some	of	 the	 first	 approaches	 at	 human	 lens	 regeneration	 (i.e.,	 attempts	 at	 producing	 a	chitosan-based	explant	pair	system);	these	difficulties	required	consideration	of	an	alternate	approach.	A	wider	understanding	of	lens	biology	gave	rise	to	the	idea	of	trying	to	mimic	non-human	lens	developmental	in	the	lab,	inspired	by	teleost	lens	development.	This	LEC	aggregation	method	was	made	possible	by	thinking	laterally	and	using	simple,	available,	materials	to	replicate	embryonic	aspects	of	teleost	lens	development.	This	method	ultimately	proved	successful	in	producing	human	PS	cell-derived	 micro-lenses.	 Furthermore,	 the	 rapid	 assessment	 lesson	 learned	 by	experiencing	 some	unworkable	 situations	 in	 the	 course	 of	 the	 project	were	 then	applied	during	 the	hydrogel	3D	growth	environment	 trials.	Repeatable	 aggregate	loss	 in	some	hydrogels	confirmed	that	 the	agarose-based	gels	best	supported	the	developing	micro-lenses	and	facilitated	progression	of	investigation	of	micro-lenses	derived	from	enriched	ROR1	cells.	Additionally,	this	project	was	not	without	its	share	of	failures.	Reflection	upon	these	challenges	and	ascertaining	the	reasons	for	(and	ways	to	move	beyond)	them	have	changed	my	approach	to	managing	difficulties	and	improved	 my	 analytical	 abilities.	 These	 skills	 will	 be	 applied	 to	 my	 future	undertakings.		
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1.1 Cataract 
The	eye’s	 lens	must	be	transparent	with	a	high	refractive	 index	 in	order	to	 focus	light	 onto	 the	 retina.	 Cataract	 is	 a	 pathological	 condition	 that	 results	 in	 loss	 of	transparency	due	to	increased	light	scatter	in	the	lens,	resulting	in	impaired	vision	or	blindness.	Cataract	is	prevalent	in	our	ageing	population	and	the	leading	cause	of	preventable	 blindness	 worldwide	 (1).	 Cataract	 accounts	 for	 35%	 of	 blindness	globally,	 affecting	 approximately	 12.6	 million	 people	 in	 2015	 (2).	 By	 2020	 the	estimated	number	of	people	worldwide	to	be	blinded	by	cataract	is	13.4	million	(2).	A	further	57.1	million	people	worldwide	are	predicted	to	have	moderate	to	severe	visual	impairment	resulting	from	cataract	(2).	This	continues	a	decades-long	trend	of	 increasing	blindness/low	vision	due	to	cataract	 from	50.5	million	combined	in	1990	to	65.2	million	in	2015,	and	70.5	million	predicted	in	2020	(2).	Currently,	 the	 only	 treatment	 available	 for	 cataract	 is	 surgical	 implantation	 of	 a	plastic	intra-ocular	lens	(IOL),	and	this	surgery	is	increasing	in	demand	by	an	ageing	population.	 Cataract	 surgery	 is	 one	 of	 the	 most	 commonly	 performed	 surgical	procedures	in	the	world	yet	the	current	levels	of	surgery	are	too	low	to	cope	with	the	 load	of	patients	with	cataract	(3).	Additionally,	due	to	population	ageing,	 it	 is	expected	that	there	will	be	and	increased	demand	for	cataract	surgeries;	the	number	of	people	with	moderate	to	severe	visual	impairment	due	to	cataract	is	expected	to	increase	 by	 8%	between	 2015	 to	 2020	 (2)	 due	 to	 increased	 life	 expectancy	 and	growth	 in	 ageing	 populations	 (4).	 The	World	 Health	 Organization	 (WHO)	 global	action	plan	(5)	aims	to	decrease	preventable	blindness	by	25%	between	2010	and	2019,	prioritizing	cataract	(4).	Countries	with	a	low	human	development	index	and	lower	 gross	 domestic	 product	 per	 capita	 have	 a	 strong	 correlation	 with	 low	numbers	of	cataract	surgery	(6).	In	developing	countries,	it	can	be	difficult	to	access	cataract	surgery;	 for	 instance,	many	patients	are	hindered	by	poverty	and/or	the	difficulty	travelling	to	cities	from	rural	areas	(7).	Additionally,	a	 large	backlog	for	cataract	surgery	exists	due	to	both	low	available	resources,	and	time	taken	to	train	surgeons	(8).		
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In	 developing	 countries,	 such	 as	 Bangladesh	 and	 the	 Philippines,	 the	 economic	burden	of	cataract	is	not	limited	to	a	decreased	ability	of	the	patient	to	work	(9).	Often,	a	secondary	consequence	of	cataract-induced	vision	loss	or	blindness	is	the	loss	of	income	for	a	second,	otherwise	productive,	family	member,	who	is	required	to	 become	 a	 full-time	 carer	 for	 the	 untreated	 cataract	 patient	 (9).	 In	 addition	 to	direct	costs	of	cataract,	loss	of	productivity	(10)	and	social	isolation	(11)	negatively	affects	the	quality	of	life	for	the	cataract	patient	(8).		Good	quality	vision	is	usually	restored	immediately	after	cataract	surgery,	though	posterior	 capsule	opacification	 (PCO)	 is	 a	 common	side-effect	 that	often	appears	after	 2	 or	 more	 years	 in	 a	 large	 number	 of	 patients	 and	 requires	 additional	treatment	 to	maintain	visual	acuity.	The	costs	of	 treating	cataract	worldwide	are	increasing	annually	due	to	an	increasing	ageing	population	(4).	The	direct	cost	of	cataract	 treatment	 was	 $326	 million	 in	 Australia	 in	 2004	 (1).	 Internationally,	billions	 of	 dollars	 are	 spent	 each	 year	 on	 cataract	 surgery.	 Identification	 of	 risk	factors	 for	 cataract	 and	and	understanding	of	 their	molecular	mechanisms	 could	lead	to	identification	of	strategies	that	prevent	or	delay	cataract,	thereby	minimising	the	debilitating	effects	and	high	costs	of	cataract-related	vision	loss.	Cataract	surgery	involves	the	removal	of	the	cataract-affected	lens	from	the	eye	–	via	phacoemulsification	–	followed	by	implantation	of	an	IOL	within	the	remaining	lens	 capsular	 bag	 (a	 thin,	 transparent	 membrane	 that	 surrounds	 the	 lens).	 As	mentioned,	PCO	is	a	prevalent	complication	that	can	follow	IOL	implantation	(12).	PCO	occurs	when	lens	cells	not	removed	during	primary	cataract	surgery	proliferate	and	migrate	to	the	posterior	lens	capsule	and	cause	abnormal	lens	capsule	wrinkling	(13).	The	overall	incidence	of	secondary	cataract	has	been	reported	to	be	28%	at	5	years	after	cataract	surgery	(14).	However,	this	increases	to	up	to	70%	in	patients	under	40	years	of	age	(13)	and	90%	of	pediatric	cataract	patients	when	the	posterior	capsule	 remains	 intact	 (15).	 Treatment	 of	 PCO	 generally	 involves	 posterior	capsulotomy	using	a	neodymium-doped	yttrium	aluminium	garnet	(Nd:YAG)	laser	(16).	Hydrophobic	IOL	implants	may	reduce	or	delay	the	incidence	of	PCO	compared	to	hydrophilic	IOLs	(14,17).	However,	any	intervention	after	the	primary	cataract	surgery	 leads	to	higher	overall	monetary	cost	preceded	by	a	period	of	 increasing	functional	vision	impairment	for	the	patient	over	the	course	of	a	few	years.	
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Despite	cataract	being	prevalent	in	the	ageing	population,	congenital	and	childhood	cataract	 can	 also	 occur	 with	 devastating	 effects,	 particularly	 on	 the	 social	 and	intellectual	development	of	 the	patient	(10).	Pediatric	cataract	 is	one	of	 the	most	common	causes	of	blindness	in	children,	particularly	in	the	developing	world	(18).	Early	 recognition	 and	 treatment	 of	 lens	 opacity	 is	 essential	 to	 avoid	 deprivation	amblyopia	 (18)	 whereby	 loss	 of	 vision	 in	 critical	 neurological	 developmental	periods	 can	 cause	 permanent	 blindness.	 Congenital	 cataract	 requires	 early	intervention	to	prevent	amblyopia	and	surgery	often	takes	place	as	early	as	8	to	12	weeks	of	age	(19).	Infants	may	be	implanted	with	an	IOL	at	this	stage	(if	access	to	follow-up	 surgery	 is	 limited;	 in	 these	 cases,	 the	 children	 require	 corrective	spectacles	 initially	before	 the	child	 ‘grows	 into’	 the	corrective	power	of	 the	 IOL).	Alternately,	 and	 more	 typically	 in	 developed	 countries,	 the	 childhood	 cataract	patient	does	not	undergo	IOL	implantation	after	cataract	removal.	Instead,	the	child	remains	aphakic	for	up	to	2	to	10	years	to	allow	the	child’s	eye	to	grow.	During	this	time,	 visual	 correction	 is	 provided	 by	 aphakic	 glasses	 or	 contact	 lenses	 (when	environmentally	appropriate,	e.g.	not	in	the	Middle-East)	until	IOL	implantation	at	a	later	date	(19).	These	approaches	all	require	multiple	surgical	interventions	and	the	glasses/contact	 lens	management	techniques	are	often	difficult	and/or	highly	traumatic	for	the	patients	and	their	families	(20).	
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1.1.1 Cataract risk factors Cataract	can	be	classified	in	a	number	of	ways,	including	the	location	in	the	lens	and	the	 characteristics	 of	 the	 opacified	 area.	 The	most	 common	 cataract	 type	 is	 age-related	 nuclear	 cataract	 (ARN)	 (21,22).	 Other	 types	 of	 cataract	 such	 as	 cortical	cataract	 demonstrate	 a	 variety	 of	 forms	 including	 radial,	 dot	 and	 spoke	 shaped	opacities	(23).	Multiple	cataract	risk	 factors	(Table	1.1)	have	been	postulated	 for	age-related	 cataract;	 however,	 their	 mechanisms	 of	 action	 are	 yet	 to	 be	 fully	established.	Examples	of	end-point	molecular	changes	thought	to	be	responsible	for	disruption	of	light	transmission	through	the	lens	include	misfolding	and	aggregation	of	lens	crystallin	proteins	in	the	lens	(24-27)	and	the	development	of	multi-lamellar	membrane	bodies	(28).	Color	changes	of	the	lens	can	also	occur,	termed	brunesence,	that	have	been	attributed	to	crystallin	glycation	and	the	Maillard	reaction	of	sugars	in	 the	 lens	 (23,29).	 Single	 nucleotide	 polymorphisms	 (SNPs)	 have	 also	 been	correlated	 with	 cataract	 in	 gene-gene	 and	 gene-environmental	 analyses	 (30).	Difficulties	 arise	 in	 determining	 the	 causative	mechanisms	 of	 cataract	 in	 human	lenses	 due	 to	 severe	 difficulties	 in	 accessing	 useful	 quantities	 of	 intact/non-phacoemulsified	 human	 lenses	 or	 lens	material	 across	 the	 timeframe	 of	 cataract	development	(particularly	the	early	stages).			
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Table 1.1 Cataract types and risk factors 
Risk factor Type Proposed mechanism 
metal ion and tryptophan 
metabolites (31) nuclear crystallin cross-linking 
cigarette smoking 
(32,33) nuclear, posterior subcapsular metal ions 
hyperglycaemia 
(34,35) 
nuclear, posterior subcapsular, 
cortical glycation of crystallin 
radiation: UV, electromagnetic, 
ionizing (36-38) posterior subcapsular, cortical 
includes instantaneous, long 
and short-term exposure 
drugs (39) posterior subcapsular long term use of corticosteroids 
alcohol (40) age-related 
cytochrome-induced oxidation 
/ 
increased Ca permeability 
age (41) age-related nuclear multilamellar bodies 
age (42) age-related post-translational modification - methylation 
multifactorial (32) age-related both multiple genes and environmental factors 
oxidative stress (29,43) age-related miRNA regulation of oxidative stress genes, Maillard reaction 
altered crystallin 
transcriptional activity (30,44) age-related 
CRYAA polymorphisms SNPs 
in ARC-susceptible Han 
population 
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	Ideally,	investigation	of	cataract	risk	factors	requires	a	suitable	3-dimensional	(3D)	human	lens	model	–	capable	of	light	transmittance	and	focusing	ability	-	in	order	to	examine	how	the	molecular	mechanisms	of	cataract	formation	lead	to	loss	of	lens	function.	Such	a	model	must	be	accessible	at	every	stage	of	cataract	development	and	 available	 in	 sufficient	 quantities	 to	 enable	 analysis	 of	 multiple	 replicates	 of	exposure	to	suspected	cataract	causing	agents	via	a	range	of	detection	techniques.	The	 ability	 to	 test	 cataract	 risk	 factors	 such	 as	 smoking	 (33,45),	 oxidation	(21,23,33,46,47),	 diabetes	 (34,35),	 electromagnetic	 radiation	 (48-50),	 ageing	(23,29,51),	 UV	 light	 (24,38)	 and	 drugs	 in	 an	 in	 vitro	 human	 lens	 model	 would	provide	much-needed	insight	into	the	mechanisms	operating	at	all	stages	of	cataract	formation	–	with	concomitant	identification	of	candidate	pharmacological	targets	to	delay	or	treat	risk	factor-specific	cataract	types.	
1.2 Lens biology as a template for in vitro lens 
generation 
Typical	approaches	to	enabling	 investigation	of	cataract	risk	factors	have	been	 in	
vivo	and/or	in	vitro	analysis	of	animal	lens	models.	These	studies	require	detailed	comprehension	 of	 lens	 anatomy,	 molecular	 biology	 and	 development	 and	 have	provided	 further	 understanding	 of	 human	 lens	 biology.	 The	 following	 section	reviews	what	is	known	about	these	processes.	
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1.2.1 Lens anatomy Anatomically,	 the	 lens	 is	 a	 transparent,	 biconvex,	 avascular	 and	 non-innervated	tissue	located	near	the	anterior	of	the	eye,	posterior	to	the	cornea	and	iris	(Figure	1.1).	After	light	enters	the	eye	through	the	cornea,	the	lens	focuses	it	onto	the	retina.	Lens	 function	 is	 intimately	 linked	 to	 its	anatomical	 features.	Postnatally,	 the	 lens	consists	of	 two	cell	compartments,	 lens	epithelial	cells	(LECs)	and	 lens	 fiber	(LF)	cells	(Figure	1.2).	The	LECs	form	an	anterior	monolayer	of	cuboidal	cells	that	are	normally	quiescent	in	the	postnatal	period	apart	from	a	ring	of	cells	anterior	to	the	lens	equator	(27).	The	progeny	of	these	cells	then	gave	rise	to	immature	LF	cells.	Lens	growth	occurs	through	addition	of	new	‘shells’	of	‘secondary’	LF	cells	around	previously	generated	LF	cells.	The	oldest	(i.e.,	primary)	LF	cells	are	located	within	the	center	(or	nucleus)	of	the	lens	and,	as	described	in	more	detail	in	Section	1.3,	these	 oldest	 of	 LF	 cells	 are	 formed	 during	 embryonic	 development	 (52).	 The	production	of	secondary	LF	cells	involves	extensive	cell	elongation	to	create	highly	ordered	and	tightly-packed	concentric	shells	of	cortical	LF	cells	that	have	flattened	hexagonal	cross-sections	(53)	that	overlay	the	older	cells	of	the	lens	nucleus	(54).	The	apical	tips	of	the	elongated	lens	cells	typically	have	an	apical-apical	interaction	with	other	lens	cells,	forming	the	anterior	lens	suture.	In	contrast,	the	basal	tips	of	the	LF	cells	maintain	attachment	to	the	lens	capsule	until	they	reach	and	contribute	to	the	posterior	lens	suture	(55).	The	lens	sutures	in	primates	have	more	complex	branching	than	in	other	animals,	over	12	branches	in	adult	humans	(56,57).	Lens	sutures	are	thought	to	allow	for	the	ends	of	the	LF	cells	to	controllably	realign	when	the	lens	accommodates,	i.e.	changes	shape	to	focus	(56).	
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Other	key	features	of	LF	cell	differentiation	include:	expression	of	large	amounts	of	crystallin	proteins	(that	provide	the	lens	with	its	required	refractive	index);	and	the	establishment	 of	 an	 organelle	 free	 zone	 (OFZ)	 via	 controlled	 degradation	 of	 all	organelles	 (thereby	 increasing	 lens	 transparency	 by	 removing	 potentially	 light-scattering	particles	from	the	light	path	of	the	lens	including	the	cell	nucleus)	(58-60).	 Nuclear	 degradation	 is	 a	 key	 process	 that	 contributes	 to	 maximal	 light	transmission	and	reduced	light	scatter.	Establishment	of	the	OFZ	occurs	in	the	pre-natal	 period;	 however,	 this	 process	 has	 not	 been	 well	 documented	 in	 humans	(60,61).	 Studies	of	 early	 lens	development	have	 relied	mainly	on	 embryonic	 and	postnatal	 chick,	 or	 mouse	 and	 rat	 lenses	 to	 examine	 nuclear	 and/or	 organelle	degradation	 (58,62-65).	 Denucleation	 and	 organelle	 loss	 occurs	 may	 involve	autophagy	(58);	however,	the	mechanisms	involved	are	not	fully	clear.			
 25 
				
	
 
Figure 1.1 Structure of the eye  
A cross-sectional diagram of the eye showing the location of the lens and other primary eye structures, 
as indicated. The lens is shown in blue (modified from (66)). 	
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Figure 1.2 Structure of the mammalian lens  
This diagram indicates the location of the anterior lens epithelial monolayer, transitional zone where LF 
cell differentiation begins, the lens nucleus (containing the primary LF cells), and the layers of secondary 
LF cells overlaying lens nucleus (54). 		
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The	predominant	proteins	within	the	lens	are	the	abundantly	expressed	crystallins	(67).	LF	cells	express	α-,	β-	and	γ-crystallin	proteins,	whereas	LECs	express	only	α-crystallin	protein	(68).	A	marker	of	LF	cells	undergoing	elongation	is	expression	of	β-	and	γ-crystallin	proteins,	concomitant	with	abundant	production	of	α-	crystallin	(69,70).	The	high	concentration	of	crystallin	in	the	lens,	approximately	50%	of	the	wet	weight,	and	the	high	refraction	of	the	amino	acids	that	compose	γ-crystallin	(71)	contribute	 to	 the	high	 light	 transmission	properties	of	 the	 lens.	 Interestingly,	 the	crystallin	proteins	of	the	lens	nucleus	are	present	at	birth	and	exist	throughout	life	without	 being	 replaced	 (as	 terminally	 differentiated	 cells	 have	 lost	 their	transcriptional	 machinery)	 (65).	 They	 are	 therefore	 amongst	 the	 longest-lived	proteins	in	the	body	(72).	Likewise,	LF	cells	do	not	turn	over,	and	the	lens	continues	to	grow	throughout	life	by	addition	of	LF	cell	layers	(52).	The	longevity	of	crystallin	proteins	 makes	 them	 susceptible	 to	 loss	 of	 solubility,	 aggregation	 and	 post-translational	modifications	that	are	among	the	speculated	mechanisms	of	cataract	formation.		The	lens	capsule	(that	surrounds	the	lens)	is	the	thickest	basement	membrane	in	the	body	(73,74)	and	contributes	to	its	ellipsoidal	shape	(53,75).	The	lens	capsule	also	has	a	role	in	cell	signalling	in	the	developing	and	mature	lens	(73).	Lens	capsule	proteins	are	secreted	by	both	LECs	and	LF	cells	(73)	and	include	collagen	IV	(the	most	 abundant),	 laminin,	 perlecan	 and	 entactin/nidogen	 (76).	 These	 proteins	provide	protection	and	structure	to	the	lens	(73)	while	still	providing	permeability	to	nutrients	and	growth	factors	(77).		
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1.3 Mechanisms of lens development  
1.3.1 Mammalian lens development The	structure	of	 the	mature	 lens	described	above	 is	a	consequence	of	a	series	of	events	that	occur	during	embryonic	development.	In	mammals,	lens	development	begins	 with	 a	 thickening	 of	 the	 lens	 placode	 (Figure	 1.3),	 a	 section	 of	 surface	ectoderm	 in	 the	 early	 embryo	 (78).	 The	 cells	 of	 the	 lens	 placode	 proliferate,	invaginate,	then	close	and	separate	from	the	lens	placode	to	form	the	lens	vesicle	
(78).	Cells	 in	 the	posterior	section	of	 this	 spherical	monolayer	of	 lens	progenitor	cells	 then	 differentiate	 into	 primary	 LF	 cells	 in	 response	 to	 relatively	 high	concentrations	 of	 fibroblast	 growth	 factor	 (FGF)	present	 in	 the	 vitreous	humour	(Figure	1.1)	(75,79,80).	Elongation	of	the	primary	LF	cells	fills	the	lumen	of	the	lens	vesicle,	 generating	 the	 basic	 lens	 structure.	 Maturation	 of	 the	 primary	 LF	 cells	involves	 nuclear	 and	 organelle	 degradation	 and	 expression	 of	 specific	 β-	 and	 γ-crystallin	proteins	(27).	Mammalian	lens	development	reflects	genetic	similarities	with	other	species,	including	some	invertebrates,	even	though	the	resulting	lenses	exhibit	distinct	morphological	differences	(81).	There	are	a	number	of	conserved	genes	and	gene	regulatory	networks	that	are	highly	conserved	in	both	mammals	and	other	 species	 (81).	 For	 example,	 transcription	 factors	Pax6	and	 the	 Sox	 family	 is	conserved	 in	 invertebrates	 such	 as	 Drosophila	 in	 addition	 to	 vertebrates	 and	mammals	 functioning	 in	 both	 as	 induction	 of	 the	 lens	 placode	 and	 LF	 cell	differentiation	 (81).	 Regulatory	 signalling	 pathways	 involving	Wnt	 and	 BMP	 are	conserved	across	vertebrate	species	(81,82).	Likewise,	cell	adhesion	molecules	E-cadherin	and	N-cadherin	are	expressed	in	both	invertebrate	and	vertebrate	lenses	(81).	Additionally	the	predominant	lens	protein	crystallin	is	highly	conserved	at	the	gene	level	and	have	widespread	expression	in	the	lens	among	species	(71,82-85).	Lens	growth	continues	throughout	 life	as	a	result	of	LEC	proliferation	at	 the	 lens	equator,	followed	by	differentiation	to	secondary	LF	cells	that	form	layers	of	tightly	packed,	elongated,	LF	cells	that	overlay	the	older	cells	of	the	lens	nucleus	(Figure	1.2)	(53).			
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1.3.2 Teleost lens development Like	 early	 mammalian	 lenses,	 lens	 development	 in	 teleost	 species	 such	 as	 the	Zebrafish	 (Danio	 rerio)	 commences	 with	 a	 thickening	 of	 the	 lens	 placode	 and	proliferation	of	these	lens	progenitor	cells	(86).	However,	in	contrast	to	mammalian	lens	development,	these	proliferating	lens	progenitor	cells	form	a	solid	aggregate	of	cells	(87)	called	a	lens	cell	mass	(i.e.,	not	a	lens	vesicle	with	an	acellular	lumen).	This	lens	cell	mass	separates	from	the	lens	placode	(Figure	1.3),	after	which	cells	within	the	 lens	 cell	mass	 differentiate	 to	 form	 primary	 LF	 cells.	 Secondary	 LF	 cells	 are	added	 in	 a	 concentric	 arrangement	 similar	 to	 the	 process	 described	 above	 for	mammalian	lenses.	The	mature	Zebrafish	lens	structure	is	almost	spherical	during	prenatal	development	(rather	than	ellipsoid	as	in	humans)	yet	the	final	lens	shape	has	distinct	and	recognizable	similarities	to	a	mammalian	embryonic	lens	(88).		
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Figure 1.3 Comparative development of mammalian and teleost lenses  
The mammalian lens (left) is formed from a thickened lens placode (left, top) that extends and invaginates 
to form a vesicle lined with a monolayer of LECs that differentiate, at the equator of the vesicle, to produce 
LF cells that fill the vesicle (left, bottom). The Zebrafish lens (right) commences development with a 
thickening of the lens placode (right, top) that continues to thicken and form a ball-like mass that 
separates as LF cells are added in a concentric configuration (right, bottom). (Modified from (87)). 
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The	differing	early	developmental	structures	of	mammalian	and	teleost	lenses	result	in	broadly	similar	 lens	structures	and	functions.	 In	the	 laboratory,	 formation	of	a	lens	 vesicle-like	 structure	 comprised	 of	 paired	 rat	 LEC	 explants	 (Figure	 1.4)	 has	been	used	to	generate	functional	(Figure	1.5),	physiologically-sized	rat	lenses	(89).	The	 time	 and	 labor-intensive	 nature	 of	 that	 system	 restricts	 its	 capacity	 to	generating	 only	 small	 numbers	 of	 rat	 lenses	 in	 vitro	 for	 studies	 of	 cataract	development	(89).	Also,	it	still	represents	an	animal-based	model	of	lens	function.	A	simple	 and	 robust	 system	 for	 reproducibly	 generating	 large	 numbers	 of	 light-focusing	 human	 lenses,	 perhaps	 by	 gaining	 insight	 from	 an	 aspect	 of	 the	 teleost	developmental	morphology	and	arranging	a	quantity	of	ROR1+	LECs	into	a	spherical	shape	 that	 resembles	 the	 ball-like	mass	 of	 teleost	 lenses	 to	 produce	human	 lens	tissue	in	vitro,	could	benefit	study	of	lens	development	and	cataract.			
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Figure 1.4 Rat explant pair-based lens regeneration 
Schematic diagram showing how the anterior epithelial monolayer of rat lenses were harvested, trimmed 
to remove partly differentiated equatorial LF cells then paired to simulate the lens vesicle in vitro. 
Placement of the bottom LEC monolayer in contact with the plastic culture dish provided an 
approximation of the polarized exposure to vitreous fluid seen in vivo. (89).  	
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Figure 1.5 Rat lens explant pair produced a lens that had focusing ability 
A light-focusing in vitro rat lens generated from paired rat LEC explants demonstrating the ability of these 
in vitro generated tissues to focus light. Scale bar 500 μm (89) 	
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1.4 The necessity for an in vitro human lens model 
Morphological	and	genetic	differences	between	species	mean	that	the	current	use	of	animal	lens	models	may	be	insufficient	to	address	the	need	for	research	on	human	lens	 tissue	 (22).	 Likewise,	human	 lens	 tissue	 from	 the	embryonic	developmental	phase	or	healthy	and	light-focusing	adult	human	lens	tissue	are	difficult	to	procure	(22).	Human	pluripotent	stem	(PS)	cells	are	an	emerging	technology	that	enables	large-scale	production	of	normal	or	diseased	human	cells	or	tissue.	Development	of	a	 human	 lens	model	 that	possesses	 similar	 functional,	 anatomical	 and	molecular	properties	to	normal	human	lenses	-	particularly	the	ability	to	focus	light	-	as	well	as	the	ability	to	be	produced	in	large	quantities	could	fulfil	the	need	for	studies	of	lens	 development,	 assessment	 of	 cataract	 risk	 factors,	 clinically	 relevant	 toxicity	assays	 and	anti-cataract	drug	 screening.	Candidate	drugs	 that	 can	 cause	 cataract	could	be	utilized	to	validate	a	lens	tissue	model.		Encouragingly,	 human	 PS	 cells	 can	 be	 differentiated	 via	 a	 3-stage	 protocol	 into	heterogeneous	 populations	 containing	 lens	 cells	 (90).	 Several	 groups	 have	attempted	to	produce	human	lens-like	tissues	after	generating	lens	cells	following	the	3-stage	method	(91-93).	However,	rudimentary	lens	tissues	produced	using	any	of	these	methods	have	key	limitations,	including	abnormal	surface	attachment	and	lack	of	demonstrated	light	focusing	ability	(91).	Functional	human	lens	tissue	would	be	an	invaluable	aid	to	further	lens	biology	research	and	gain	a	better	understanding	of	molecular	mechanisms	of	cataract,	particularly	if	human	lens	tissue	models	could	be	generated	simply	and	efficiently	in	large	numbers.	
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1.5 The role of pluripotent stem cells in in vitro lens 
production 
Much	 of	 our	 understanding	 of	 early	 lens	 development	 has	 been	 obtained	 by	investigating	animal	models	that	have	developmental	and	physiological	similarities	to	 humans.	 However,	 the	 development	 of	 human	 PS	 cell	 technology	 offers	 the	opportunity	to	generate	large	numbers	of	normal	(or	diseased)	human	cells	in	vitro.	This	is	because	human	PS	cells	can	differentiate	into	any	cell	type	in	the	body,	given	the	appropriate	spatio-temporal	combination	of	growth	factors.	Human	PS	cells	are	able	 to	 indefinitely	 self-renew	 due	 to	 high	 levels	 of	 telomerase	 expression	 that	maintains	the	telomere	length	and	is	associated	with	human	cell	 line	immortality	(94).	The	most	commonly	used	human	PS	cells	are	embryonic	stem	(ES)	cells	and	induced	pluripotent	stem	(iPS)	cells.		Human	ES	cells	are	obtained	from	surplus	preimplantation	stage	blastocysts	(5	to	14	 days	 post-fertilisation)	 (94-96),	 donated	with	 informed	 consent	 from	 in	 vitro	fertilisation	programs	(97).	Human	ES	cells	are	obtained	from	the	inner	cell	mass	(94,96)	of	human	blastocysts	5	to	14	days	post	fertilisation.	At	this	stage,	the	embryo	is	 composed	 of	 the	 trophoblast	 that	 forms	 the	 outer	 layer	 (cytotrophoblast	 for	attachment	to	the	uterine	wall)	and	placenta	(syncytiotrophoblast),	and	the	inner	cell	mass	that	undergoes	gastrulation	to	form	the	embryo	(95).	Human	PS	cell	lines	can	 be	 also	 be	 derived	 from	 a	 single	 cell	 blastomere	 that	 is	 removed	 during	preimplantation	genetic	diagnosis	(PGD)	(98).	Notably,	human	ES	cell	lines	can	be	derived	 from	normal	embryos,	or	embryos	containing	disease-causing	congenital	mutations	identified	via	PGD.	In	contrast,	human	 iPS	cells	are	somatic	cells	 that	have	been	reprogrammed	to	a	pluripotent,	 embryonic-like	 state	 by	 forced	 expression	 of	 transcription	 factors	involved	in	pluripotency	(99,100).	Human	iPS	cells	can	be	used	to	generate	normal	or	 patient/disease	 specific	 pluripotent	 cell	 lines	 with	 which	 to	 study	 the	mechanisms	of	the	disease	in	an	in	vitro	model	(101).	Human	iPS	cells	avoid	some	of	the	ethical	issues	associated	with	the	derivation	of	human	ES	cells	and	can	also	provide	the	ability	for	disease	modeling	without	the	need	for	PGD.		
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1.5.1 Production of lens cells from human PS cells in vitro The	 3-stage	 growth	 factor	 method	 for	 generating	 heterogeneous	 populations	 of	LECs	and	subsequently,	LF	cells,	from	human	ES	cells	was	published	in	2010	(Figure	1.6)	 (90).	 The	 method	 involves	 exposure	 to	 a	 progressive	 sequence	 of	 growth	factors	 that	 regulate	 cell	 fate	 chosen	 to	 mimic	 aspects	 of	 embryonic	 lens	development	in	vitro.	The	first	stage	introduces	Noggin	for	6	days	to	inhibit	Bone	Morphogenic	 Protein	 (BMP)	 signalling	 and	 thus	 differentiate	 the	 human	ES	 cells	towards	a	neuroectoderm	fate	(90).	The	12-day	long	second	stage	introduces	BMP4	and	BMP7,	as	well	as	Fibroblast	Growth	Factor	2	(FGF2)	to	induce	production	of	lens	placodal	 cells	 (i.e.,	 LEC	 progenitor	 cells)	 (90).	 A	 third	 stage	 that	 uses	 FGF2	 and	WNT3a	stimulates	differentiation	of	LECs	to	LF	cells	(85,90).		This	3-stage	method	represents	a	simplification	of	the	growth	factor	regulation	of	the	 lens	 developmental	 process.	 First	 the	 development	 of	 neuroectoderm	 is	prompted	by	Noggin,	an	antagonist	of	BMP	(102),	followed	by	induction	of	LECs.	The	growth	factors	FGF	and	BMP	interplay	to	promote	LEC	differentiation,	with	a	low	concentration	 of	 FGF	 encouraging	 proliferation	 of	 LECs	 (103).	 The	 final	 stage	represents	the	most	complex	growth	factor	relationships.	Wnt	regulates	embryonic	lens	formation	and	is	a	highly	conserved	molecule	amongst	different	species	(104).	Wnt	is	important	for	elongation	and	primary	LF	cell	differentiation	(102,104)	as	it	is	 implicated	 in	 cytoskeletal	 arrangement	 (103)	 and	 migration;	 explanted	 LECs	migrate	along	a	Wnt	gradient	(75).	The	growth	factor	FGF	is	required	for	induction	of	LF	cell	fate	from	LECs	(104)	with	a	dose	dependent	respose;	low	concentratons	of	FGF	promote	proliferation	of	LECs	and	a	higher	dose	promotes	LF	differentiation	(75,103).	Together	with	FGF,	Wnt	modulates	the	transition	of	LECs	to	LF	cells	using	the	aforementioned	3-stage	method	(90),	although	the	mechanisms	of	Wnt	and	FGF	signalling	together	remain	unclear	(102).	The	effectiveness	of	this	3-stage	protocol	is	 demonstrated	 by	 the	 fact	 that	 it	 has	 been	 replicated	 by	 a	 number	 of	 research	groups	using	a	variety	of	human	PS	cells	(91-93).			
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Figure 1.6 Generation of lens cells from human PS cells 
The 3-stage process introduces a sequence of growth factors that stimulate human PS cells towards a 
neuroectoderm fate followed by lens cell production, resulting in a heterogeneous mixture of non-lens 
cells and spontaneously generated ‘lentoids’ that contain LECs and LF cells. Adapted from (90). 
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	Whilst	this	elegant	3-stage	lens	differentiation	method	(90)	does	produce	LECs	and	LF	 cells,	 the	 method	 does	 have	 some	 important	 limitations.	 The	 resulting	 cell	population	 is	 a	 heterogeneous	 mixture	 of	 LECs,	 LF	 cells	 and	 non-lens	 cells.	 An	impure	 population	 of	 cells	 gives	 uncertainty	 as	 to	 the	 cell	 type	 obtained	 when	harvesting	the	cells	for	downstream	applications.	The	inability	to	selectively	harvest	pure	LECs	or	LF	cells	from	the	originally	published	differentiation	method	can	make	interpretation	of	data	from	this	system	challenging.		Additionally,	random	production	of	lens-like	tissue	occurs	in	the	later	stages	of	cell	cultures	 following	 the	 3-stage	 method	 (90).	 Production	 of	 abnormally	 adherent	lens-like	clusters	-	called	lentoids	-	occurs	randomly	in	the	culture	dish.	The	lentoids	produced	are	then	frequently	observed	to	be	lost	from	the	culture	surface	into	the	culture	medium	(90).	Furthermore,	the	 lentoids	have	no	reported	ability	to	focus	light,	a	fundamental	requirement	of	the	lens	(105).	This	is	unsurprising	given	the	highly	organized	nature	of	the	lens	and	the	relatively	disorganized	structure	of	these	spontaneously	generated	lentoids.	Similar	data	have	been	obtained	by	other	groups.	For	example,	Qiu	et	al,	(106)	recently	harvested	lens	cells	from	a	cataract	patient,	reprogrammed	them	to	a	pluripotent	state,	then	differentiated	the	resulting	iPS	cells	to	 become	 lens	 cells.	 As	 with	 Yang	 et	 al,	 this	 approach	 yielded	 a	 mixed	 cell	population	of	non-lens	cells,	LECs	and	LF	cells	(90).	Comparably,	Li	and	colleagues	(93)	 harvested	 cells	 from	 the	 anterior	 LECs	 of	 lenses	 removed	 from	 cataract	patients.	 These	 cells	 were	 induced	 to	 pluripotency	 then,	 following	 the	 3-stage	protocol	 (90),	 differentiated	back	 into	 a	 (mixed	population	of)	 LECs	 (93).	Whilst	these	studies	demonstrated	 the	possibility	of	generating	 lens	cells	 from	 iPS	cells,	with	 or	 without	 a	 genetic-based	 disease	 state,	 the	 methods	 were	 insufficiently	developed	 to	 yield	 either	 pure	 LEC	 populations	 or	 produce	 discrete	 and	 light-focusing	lens	tissue.	
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1.5.2 Improvements to lens cell production from human 
PS cells Attempts	 at	 purifying	 lens	 cells	 from	mixed	 cultures	of	 differentiating	human	PS	cells	 have	 seen	 variable	 success.	 Adopting	 an	 approach	 alternative	 to	 the	 Yang	method,	 Mengarelli	 and	 Barberi	 (107)	 cultured	 human	 ES	 cells	 in	 insulin-transferrin-selenium	(ITS)	medium	and	separated	the	resulting	mixture	of	cells	via	fluorescent	activated	cell	sorting	(FACS).	Adult	lens	surface	markers,	c-Met/HGFR	and	 CD44	were	 used	 to	 positively	 select	 and	 separate	 lens	 cells	 that	 were	 then	cultured	(107).	However	further	culture	of	these	cells	revealed	that	the	population	was	impure	and	included	neuronal	cells	(107).	Furthermore,	the	lens	cell	population	had	 poor	 survival	 and	 proliferation,	 demonstrating	 the	 necessity	 for	 a	 more	appropriate	lens	culture	medium	capable	of	retaining	the	morphology	of	the	LECs.	More	recently,	Fu	and	colleagues	(91),	generated	tens	of	lens-like	tissues	in	a	highly	manual	 and	 semi-controlled	 manner.	 While	 these	 structures	 developed	 a	 small	amount	of	magnifying	ability,	they	remained	abnormally	attached	to	the	cell	culture	dish.	More	recently,	our	group	developed	a	method	of	producing	large	numbers	of	purified	human	LECs	via	magnetic-activated	cell	sorting	(MACS)	using	an	embryonic	lens	cell-specific	marker,	the	ROR1	(receptor	tyrosine	kinase	like	orphan	receptor	1)	surface	antigen	identified	by	a	previous	PhD	student	from	our	laboratory	using	a	bioinformatic	 approach	 (108).	 These	 ROR1+	 LECs	 displayed	 similar	morphology,	gene	expression	and	protein	expression	to	human	fetal	LECs	(108).	A	subsequent	combinatorial	 growth	 factor	 screening	 approach	 identified	 a	medium	 capable	 of	proliferating	the	ROR1+	human	cells	while	maintaining	their	LEC-like	features.	This	large-scale	 source	 of	 purified	 human	 LECs	 raised	 the	 possibility	 of	 developing	 a	highly	controlled	3D	culture	system	capable	of	generating	light-focusing	human	lens	tissue.		
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1.5.3 Organoids as model tissues While	the	generation	of	human	cell	types	from	PS	cells	has	advantages	over	studies	of	animal	tissues,	investigation	of	cell	monolayers	cannot	replicate	the	finely-tuned	and	complex	interactions	produced	by	cells	within	organs.	Recent	advances	in	stem	cell	 manipulations	 in	 vitro	 have	 seen	 development	 of	 miniature-sized	 organ	counterparts	called	organoids.	These	 in	vitro	organoids	resemble	their	full-size	 in	
vivo	counterparts	in	terms	of	cell	type,	cellular	organisation	and	function.	They	have	become	an	 increasingly	utilized	 tool	 for	 the	 study	of	 organ	development	 and	 for	producing	 tissues	 for	 disease-in-a-dish	models	 (109).	 Organoids	may	 be	 derived	from	 tissue	 specific	 adult	 stem	 (AS)	 cells	 (110,111),	 human	 ES	 cells	 or	 iPS	 cells	(101,112,113).		Organoids	 have	 been	 developed	 for	 several	 tissue	 types	 thus	 far	 including	 liver	(114),	brain	(115),	intestine	(116),	lung	(117)	and	kidney	(118-120).	Rudimentary	eye-related	organoids	have	also	been	developed	 including	 the	 lentoids	described	above,	as	well	as	 retina	and	optic	cups	 (121).	These	organoids	are	being	used	 to	study	 normal	 organ	 development	 and	 diseased-state	 organs.	 For	 example,	 gut	organoids	have	been	used	for	investigation	of	the	effects	of	rotavirus	infection	in	the	intestine	(122)	and	brain	organoids	have	been	used	to	help	understand	the	effect	of	Zika	virus	(that	can	cause	microcephaly	in	the	fetus)	on	the	brain	(123).	Moreover,	organoids	 have	 the	 potential	 to	 be	 useful	 for	 drug	 toxicity	 and	 therapeutic	 drug	screening,	particularly	if	produced	in	large	quantities	(111).	Due	to	the	specialized	and	intensive	nature	of	culturing	stem	cell-derived	organoids,	production	of	large	quantities	 of	 organoids	 is	 not	 always	 possible.	 The	 ability	 to	 simply	 and	reproducibly	generate	large	numbers	of	 light-focusing	human	lenses	from	human	PS	cells	in	a	controlled	manner	would	overcome	many	of	the	limitations	inherent	to	the	 existing	 lens	 differentiation	 protocols,	 thereby	 offering	 detailed	 molecular	insights	into	human	lens	and	cataract	formation.		
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1.6 Hypothesis and aims  
1.6.1 Hypothesis That	aggregation	of	human	PS	cell-derived	purified	ROR1+	LECs	to	mimic	a	teleost	lens	 cell	mass,	 can	produce	 large	numbers	of	 light-focusing	human	micro-lenses,	suitable	for	studies	of	lens	development	and	cataract	formation. 
1.6.2 Aims 1. To	 examine	 whether	 human	 PS	 cell-derived	 purified	 ROR1+	 LECs	 can	generate	large	numbers	of	functional	micro-lenses	in	vitro.	2. To	 test	 the	 capacity	 of	 human	 PS	 cell-derived	 micro-lenses	 to	 evaluate	clinically-relevant	drug-induced	lens	toxicity	(by	assessing	the	effects	of	the	cystic	fibrosis	drug	Vx-770).	3. To	investigate	possible	improvements	to	micro-lens	production	by	assessing	alternative	starting	cells	and	growth	conditions.	
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Chapter 2 Generation of in vitro human 
micro-lenses 
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2.1 Introduction 
2.1.1 Limitations of current lens-like models The	breakthrough	method	to	produce	lens	cells	from	human	PS	cells	by	Yang	et	al.	(90)	provided	a	means	to	generate	lens	cells	and	lentoids	in	vitro.	Whilst	this	elegant	3-stage	lens	differentiation	method	(90)	produced	lens	cells,	the	method	has	some	important	limitations.	The	cell	population	produced	was	a	heterogeneous	mixture	of	 LECs,	 LF	 cells	 and	 non-lens	 cells,	 with	 up	 to	 59%	 of	 cells	 not	 expressing	 αA-crystallin.	Use	of	such	an	impure	population	of	cells	gives	uncertainty	about	the	cell	types	 being	 assessed	 and	 the	 responses	 detected	 in	 downstream	 applications.	Additionally,	 within	 this	 3-stage	 lens	 cell	 differentiation	 protocol,	 the	 lentoids	produced	are	of	variable	size,	non-adherent	and	are	lost	 into	the	culture	medium	and	subsequently	removed	during	medium	changes.	These	properties	make	them	difficult	to	capture	and	investigate.	Moreover,	these	lentoids	have	not	been	shown	to	have	measurable	light	transmission	or	focusing	capacity.	These	factors	limit	the	usefulness	of	the	produced	lentoids	to	be	harnessed	for	studying	lens	development	or	as	a	model	for	investigation	of	cataract.	As	a	result,	several	groups	have	attempted	to	 improve	the	method	to	produce	more	normal	 lens-like	tissues	 from	human	PS	cells	(91-93).		A	 useful	 system	 for	 studying	 lens	 development	 or	 for	 high-throughput	 drug	screening	 would	 have	 the	 ability	 to	 produce	 large	 quantities	 of	 non-adherent,	uniform,	light-focusing	lens-like	tissues.	A	recently	described	(91)	effort	to	produce	lens	organoids	utilized	mechanical	separation	of	lens	epithelial-like	cells,	cultured	to	produce	a	3D	structure	surrounded	by	non	LF-like	cells.	This	was	the	“fried	egg”	lentoid	body	structure	described	by	Fu	(91).	The	“fried	egg”	lentoids	demonstrated	magnification	properties;	however,	they	remained	adherent	to	a	two-dimensional	(2D)	culture	surface.	The	generation	of	“fried	egg”	lentoid	bodies	using	iPS	cells	was	highly	manual	and	laborious,	and	produced	few	lens-like	structures	(91)	therefore	is	impractical	for	use	as	a	high	throughput	drug	screening	tool.		
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2.1.2 Mimicking cross-species development to produce an 
in vitro lens There	are	several	obstacles	evident	when	devising	a	method	to	replicate	human	lens	development	in	an	in	vitro	environment.	The	mammalian	lens	development	process	involves	the	formation	of	a	lens	vesicle,	a	hollow	ball	of	LECs.	In	turn,	this	vesicle	is	exposed	 to	 a	 gradient	 of	 growth	 factors	 (including	 FGF	 signaling)	 (75,124)	 that	polarise	the	lens	to	produce	an	anterior	LEC	monolayer	and	a	large	posterior	fiber	cell	compartment.		A	 previous	 attempt	 at	 an	 in	 vitro	 lens	 generation	 by	 our	 group	 revealed	 that	 by	mimicking	aspects	of	embryonic	lens	development	in	vitro,	production	of	correctly	organized,	light	focusing	lens	tissue	was	possible	(89,125).	Key	lens	features	of	the	rat	 LEC-derived	 ‘paired	 explant’	 in	 vitro	 lenses	 included	 transparency,	 light	focussing,	 expression	 of	 mature	 lens	 proteins,	 β-crystallin	 and	 γ-crystallin	 and	organelle	loss	consistent	with	terminal	LF	cell	differentiation.	The	rat	lens	explant	pair	 demonstrated	 that	 taking	 an	 approach	 that	 replicated	 mammalian	 lens	development	 in	 vitro	 was	 sufficient	 to	 produce	de	 novo	 lens	 tissue.	 However,	 as	mentioned	above,	 the	manual	nature	of	 this	process	means	 it	 is	not	amenable	 to	generation	of	large	numbers	of	lenses	for	high-throughput	studies.	While	a	method	for	 generating	 large	 numbers	 of	 mouse	 lens	 vesicles	 in	 vitro	 has	 recently	 been	developed,	this	process	is	highly	complex	and	time	consuming	(126).	Interestingly,	differences	 in	early	developmental	pathways,	 as	previously	 shown	 in	 teleost	and	mammalian	 lenses,	can	result	 in	both	a	 functionally	and	structurally	similar	 lens.	Both	 mammalian	 and	 teleost	 lenses	 retain	 similar	 crystallin	 proteins	 (83,127),	despite	demonstration	of	different	lens	precursor	structures	(Figure	1.3)	(87).		
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Recently,	 our	 group	 recently	 published	 a	method	 for	 purification	 of	 ROR1+	 LECs	from	human	PS	cell	cultures	(108).	The	aim	of	the	work	in	this	Chapter	was	therefore	to	test	whether	these	ROR1+	cells	could	be	used	to	generate	uniformly	sized,	non-adherent	 light-focusing	 human	 lens	 tissue	 in	 vitro,	 suitable	 for	 lens	 toxicity	screening	 and	 drug	 discovery.	 Therefore,	 aggregation	 of	 human	 PS	 cell-derived	ROR1+	 lens	 cells	 into	 a	 ball-like	mass	 to	 replicate	 teleost	 lens	 development	was	tested	 for	 production	 of	 functional	 human	 lens-like	 tissue	 in	 vitro	 (128).	 This	approach	was	chosen	as	it	held	the	potential	to	generate	large	numbers	of	similarly-sized,	 and	 similarly	 developmentally-staged	 micro-lenses	 suitable	 for	 high	throughput	 drug	 screening.	 A	 commercial	 product,	 AggreWell,	 was	 used	 to	aggregate	 the	 purified	ROR1+	 lens	 cells	 to	 replicate	 the	 teleost-like	 lens	 ball-like	mass.	Using	an	AggreWell,	it	was	possible	to	generate	up	to	1200	similarly-sized	cell	aggregates	at	once	within	each	well	of	a	24-well	plate.	
2.1.3 Lens generation requires a 3D culture environment Development	and	implementation	of	a	3D	growth	environment	is	a	vital	to	provide	non-adherent	 support	 for	 aggregate	 to	 micro-lens	 growth.	 When	 cell	 culture	 is	performed	on	a	2D	flat	culture	surface,	the	majority	of	the	surface	area	of	the	cell	is	either	attached	 to	 the	 culture	vessel	or	exposed	 to	 the	medium	and	only	a	 small	surface	area	of	each	cell	is	in	contact	with	surrounding	cells.	Cell-cell	signalling	is	essential	 for	normal	 cellular	processes	 including	proliferation	and	differentiation	(129).	Furthermore,	 responses	 to	 stimuli	are	more	predictable	with	3D	organoid	forms	than	in	2D	culture	(129),	as	3D	cell	culture	more	accurately	reflects	the	in	vivo	environment	(130).	Therefore,	producing	lens-like	tissue	in	a	3D	environment	is	a	natural	progression	from,	and	improvement	to,	2D	culture.	An	advantage	that	the	aggregated	lens	cell	ball-like	mass	has	over	an	explant-pair	monolayer	is	the	3D	cell-cell	contact	that	results	from	forced	aggregation	of	the	cells.	Several	 benefits	 apply	 when	 cells	 are	 cultured	 in	 3D	 rather	 than	 traditional	 2D	culture.	The	aggregated	LEC	model	replicates	the	in	vivo	teleost	lens	development	environment,	whereby	the	majority	of	aggregated	cells	in	3D	culture	are	surrounded	by	and	interacting	with	other	cells	(131).	This	cell-cell	interaction	is	possible	in	3D	culture,	 but	 less	 so	 in	 2D	 culture,	 therefore	 aggregates	 in	 3D	 culture	 may	 have	greater	similarity	to	in	vivo	counterparts	(132).	
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A	 suitable	 3D	 growth	 environment	 must	 have	 several	 properties	 that	 allow	 for	culture	 of	 the	 lens	 cell	 aggregates.	 The	 3D	 growth	 environment	 is	 required	 to	support	and	contain	the	aggregates	(without	them	attaching	to	the	culture	vessel)	and	allow	for	nutrient	and	gas	exchange.	Likewise,	it	must	be	sufficiently	permeable	to	growth	factors	to	allow	the	correct	cell-signalling	for	differentiation	of	LECs	to	LF	cells	to	occur.	The	3D	growth	environment	must	be	adequately	transparent	to	allow	visualisation	of	the	aggregates	as	they	develop.	Ideally,	the	3D	growth	environment	will	enable	an	FGF	gradient	 to	occur.	This	would	mimic	 the	posterior-to-anterior	gradient	of	high-to-low	concentration,	that	occurs	in	the	human	eye,	to	control	the	differentiation	of	LF	cells	in	a	polarized	manner	(75).	
2.1.4 Simple, relevant quantifiable assay for cataract 
research Validation	of	any	human	lens	organoid	developed	for	cataract	research	requires	the	ability	to	induce	cataract	in	the	resulting	tissue.	A	drug	that	has	recently	commenced	use	in	treating	cystic	fibrosis,	the	chloride	channel	gating	potentiator,	Vx-770	(also	known	as	Ivacaftor,	Kalydeco)	has	been	associated	with	non-congenital	cataract	in	rat	pups	and	long-term	recipients	of	Vx-770	treatment	(133,134).	Due	to	the	risk	of	cataract	 development,	 ophthalmological	 examinations	 of	 patients	 taking	 Vx-770	were	recommended	by	the	manufacturer	(135)	and	recommendations	to	monitor	ocular	health	were	made	during	 an	 efficacy	 and	 safety	 study	over	 long-term	use	(136).	The	acknowledged	risk	of	developing	non-congenital	cataract	upon	exposure	to	 Vx-770	 indicated	 that	 this	 drug	 was	 worthwhile	 investigating	 for	 cataract	formation.	Many	of	the	patients	with	cystic	fibrosis	are	young	children,	for	whom	development	 of	 a	 cataract	would	 have	 adverse	 social	 and	 developmental	 effects	(18).		
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Exposure	of	 the	aggregated	 lens	cells	 to	clinically-relevant	doses	of	Vx-770	(137)	during	their	developmental	period	may	enable	elucidation	of	induction	of	cataract	by	this	drug.	Additionally,	candidate	drugs	that	are	known	to	cause	cataract,	such	as	corticosteroids	 (39),	 or	 are	 associated	 with	 cataract	 could	 be	 utilized	 to	 induce	cataract	 and	 validate	 a	 lens	 tissue	model.	Once	 it	 is	 known	 that	 cataract	may	be	induced,	drugs	currently	considered	 to	 reverse	cataract	 (138,139)	may	be	 tested	directly	 in	 a	human	 lens	model.	Measurement	of	 light	 transmission	and	 focusing	ability	of	lens	organoids	could	form	a	quantifiable	assay	for	the	effect	of	drugs	on	exposed	lens	organoids.		The	 addition	 of	 a	 human	 lens	 organoid	 to	 other	 currently	 developed	 human	organoid	 tissues	 could	 also	 benefit	 drug-screening	 applications.	 Intestinal	organoids	were	used	to	test	the	effects	of	Vx-770	on	the	CFTR	gene	(CFTR	F508del)	mutated	 chloride	 channel	 function.	 Interestingly,	 these	 intestinal	organoids	were	derived	from	rectal	biopsies	from	cystic	fibrosis	patients	for	the	purpose	of	a	drug	screening	assay	(110).	If	Vx-770	can	induce	cataract	in	lens	organoids,	testing	the	toxicity	of	drugs	on	different	types	of	organoid	tissues	becomes	more	relevant.	Drug	effects	may	be	 variable	between	different	 tissue	 types;	 determining	which	drugs	benefit	one	system	but	damage	another	before	they	reach	clinical	trials	in	people	is	an	ideal	outcome.		The	 aims	 for	 this	 chapter	 include	 determination	whether	 human	PS	 cell-derived	purified	ROR1+	LECs	can	be	aggregated	to	mimic	the	ball-like	mass	similar	to	teleost	lens	development	and	generate	large	numbers	of	 functional	micro-lenses	 in	vitro.	Additionally,	 such	 functional	 micro-lenses	 may	 be	 used	 to	 evaluate	 clinically-relevant	drug-induced	lens	toxicity	by	assessing	the	effects	of	the	cystic	fibrosis	drug	Vx-770	 on	 micro-lens	 development,	 light	 transmission,	 and	 light	 focusing	properties.	
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2.2 Methods 
2.2.1 Reagents and consumables  Reagents	 used	 for	 cell	 culture	 including	 mTeSR1,	 Dulbecco’s	 Modified	 Eagles	Medium	 (DMEM),	 and	 Dispase	 (Cat	 no.	 07923)	 were	 acquired	 from	 Stem	 Cell	Technologies	(Melbourne,	Australia).	Reagents	used	in	cell	harvesting	and	antibody	staining,	including	TryPLE	Express	and	Dulbecco’s	Phosphate	Buffered	Saline	(PBS)	(Gibco	 Life	 Technologies,	 Cat	 no.	 14190-250),	 were	 acquired	 from	 Invitrogen	Corporation	(Mulgrave,	Australia),	unless	stated	otherwise.	Matrigel	to	coat	tissue	culture	 plates	 was	 acquired	 from	 BD	 Biosciences	 (North	 Ryde,	 Australia).	 Rho-kinase	 inhibitor	(ROCK	inhibitor)	(Merck,	Kilsyth,	Australia)	was	used	as	an	anti-apoptotic	agent	during	cell	passaging	and	experiment	set	up.	DMEM:F12	(Thermo	Fisher,	 North	 Ryde	 NSW,	 Cat	 no.	 11330-057)	 was	 the	 base	 medium	 for	 all	differentiation	experiments.		All	tissue	culture	plates	(6-well,	96-well,	35	mm	and	60	mm,	T175	flask)	and	pipette	tips	 used	 for	 general	 cell	 culture	 were	 acquired	 from	 Greiner	 Bio-one	(Frickenhausen,	 Germany).	 General	 laboratory	 equipment	 included	 light	microscope	 (Olympus	 CKX41	 inverted	 microscope	 and	 accompanying	 digital	camera	(Olympus,	Macquarie	Park,	Australia).	A	Beckman	Coulter	Allegra®	X	-	15R	Centrifuge	 (Gladesville,	 Australia)	was	 used	 for	 volumes	 from	 1.5	mL	 to	 50	mL.	Volumes	lower	than	1.5	mL	were	centrifuged	using	a	Beckman	Coulter	Microfuge	22R	Centrifuge	or	QikSpin	Personal	Microfuge	(Edwards	Instrument	Co.,	Narellan,	Australia).	 Cells	 were	 incubated	 in	 a	 Heracell	 150	 CO2	 incubator	 at	 37	 °C,	 5	 %	(vol/vol)	CO2	(Thermo	Fisher	Scientific).	Non-sterile	pipettes	tips	and	glasswares	were	sterilized	in	a	Tuttnauer	3150EL	autoclave	(Tuttnauer,	Breda,	Netherlands).	All	culture	work	was	carried	out	in	a	Gelaire	BH	-	EN	2000	D	Series	Class	II	Biological	Safety	Cabinet	(Seven	Hills,	Australia)	with	surfaces	disinfected	with	70%	ethanol	prior	to	and	after	use.	
2.2.2 Human PS cell maintenance and harvest  The	 human	 PS	 cell	 line	 CA1	was	 used	 (provided	 by	 Prof.	 Andras	Nagy,	 Toronto,	Canada)	 (108).	 Approval	 for	 use	 of	 these	 cells	 was	 obtained	 from	 the	 Western	Sydney	University	Human	Research	Ethics	Committee	(approval	number	H10950). 
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CA1	cells	were	cultured	in	mTeSR1	and	passaged	every	7	days	as	clumps	using	1	mg/mL	dispase	(140)	on	tissue	culture	dishes	pre-coated	with	Matrigel	(0.1	mg/mL	in	DMEM)	for	30	minutes	(min)	minimum,	after	which	the	Matrigel	was	removed.	CA1	cells	were	harvested	for	differentiation	by	making	a	single-cell	suspension	from	60	mm	maintenance	plates.	In	preparation,	CA1	maintenance	plates	were	incubated	with	10	μM	of	ROCK	inhibitor	in	mTeSR1	for	1	h	minimum	at	37	°C,	5%	(vol/vol)	CO2.	A	single	cell	suspension	was	generated	using	2	mL	TrypLE	for	7	min	at	37°C,	5%	(vol/vol)	CO2.	The	cells	were	removed	from	the	culture	plastic	with	a	cell	scraper	and	pipetted	into	a	15	mL	tube.	The	plates	were	washed	with	3	mL	of	PBS	(-Ca/-Mg)	and	the	wash	added	to	the	15	mL	tube.	The	tubes	were	centrifuged	at	300	x	g	for	5	min,	the	supernatant	removed	and	discarded.	The	cells	were	resuspended	in	1	mL	mTeSR1	containing	10	μM	ROCK	inhibitor.	Cells	were	counted	by	placing	10	μL	of	the	single	cell	suspension	into	a	well	of	a	96	well	plate	and	adding	40	μL	of	trypan	blue	(Gibco,	Cat	no.	15250061).	The	cell	and	trypan	blue	mixture	was	added	to	a	haemocytometer	(Bright-Line;	Hausser	Scientific,	Pennsylvania,	USA)	and	the	cells	were	counted	using	an	inverted	light	microscope.	
2.2.3 Generation of heterogeneous cell population 
containing lens cells Single	cell	suspensions	of	CA1	cells	were	cultured	on	a	Matrigel-coated	T175	flask	in	mTeSR1	medium	until	a	tightly	packed	confluent	monolayer	was	obtained.	The	culture	medium	was	changed	to	Stage	1	medium:	DMEM:F12	containing	100	ng/mL	noggin	 (Miltenyi	 Biotech,	 Cat	 no.	 130-103-456),	 1x	 N2	 supplement	 (Gibco	 Life	Technologies,	 Cat	 no.	 17502-048)	 and	 1x	 B27	 (Gibco	 Life	 Technologies,	 Cat	 no.	17504-044)	with	daily	medium	change	 for	6	days.	The	culture	medium	was	then	changed	 to	 Stage	 2	 medium:	 DMEM:F12	 containing	 100	 ng/mL	 FGF2	 (Miltenyi	Biotech,	Cat	no.	130-093-842),	20	ng/mL	BMP4	(Miltenyi	Biotech,	Cat	no.	130-098-787)	and	20	ng/mL	BMP7	(Miltenyi	Biotech,	Cat	no.	130-103-436)	for	at	least	12	days	 with	 daily	 medium	 changes.	 The	 published	 3-stage	 process	 was	 modified	(Figure	2.1)	so	that	on	or	near	Day	18,	the	cells	were	harvested	for	purification	by	magnetic	assisted	cell	sorting	(MACS).			
 50 
	
 
Figure 2.1 Modified 3-step human PS cell differentiation process  
Schematic diagram showing the 3-stage process that induced PS cells towards the neuroectoderm fate 
then supplied growth factors that promote differentiation into lens cells. This process was modified so 
that between day 16 to 20, purified ROR1+ lens cells were extracted from the cell mixture. Adapted from 
(90). 
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2.2.4 Harvesting differentiated cells for MACS Differentiating	human	PS	cells	in	T175	flasks	were	incubated	for	60	min	with	10	μM	ROCK	inhibitor in	cell	culture	medium.	The	cell	culture	medium	was	removed	and	10	mL	TrypLE	added	and	the	flask	was	incubated	for	7	to	10	min	until	the	majority	of	cells	were	dissociated.	Remaining	attached	cells	were	removed	from	the	culture	surface	with	a	cell	scraper	and	the	cell	suspension	removed	by	pipette	to	a	50	mL	tube.	The	flask	was	rinsed	with	12	mL	PBS	(-Ca/-Mg)	and	the	PBS	collected	into	the	same	 50	 mL	 tube.	 The	 cell	 suspension	 was	 passed	 through	 a	 40	 μm	 nylon	 cell	strainer	(BD	Biosciences)	into	a	50	mL	tube.	The	cell	suspension	was	equally	divided	between	two	15	mL	tubes	then	centrifuged	at	300	x	g	for	5	min.	The	supernatant	was	removed	and	discarded,	and	the	pellets	resuspended	each	in	1	mL	of	cold	MACS	blocking	buffer	(2%	(vol/vol)	bovine	serum	albumin	(BSA)	(Miltenyi	biotech,	Cat	no.130-091-376)	 and	 2	 mM	 ethylenediamine	 tetraacetic	 acid	 (EDTA).	 10	 μL	 of	resuspended	cells	were	removed	for	a	cell	count.		
2.2.5 ROR1 antibody staining and MACS Biotinylated	antibody	was	prepared	in	advance.	Anti-ROR1	antibody	(R&D	Systems,	Cat	no.	AF2000)	was	diluted	and	biotinylated	(Miltenyi	Biotech,	Cat	no.	130-093-385)	 following	 the	 respective	 manufacturer’s	 protocols.	 The	 15	 mL	 tubes	 were	centrifuged	at	300	x	g	for	5	min.	The	supernatant	was	removed	and	discarded,	and	the	pellets	resuspended	each	in	60	μL	of	cold	MACS	buffer	(0.5%	(vol/vol)	BSA,	2	mM	EDTA)	and	40	μL	of	biotinylated	ROR1	antibody	per	approximately	3	x	106	cells,	at	ice	bath	temperature.	The	cell	and	biotinylated	antibody	mixture	were	incubated	at	4	oC	for	20	min.	1	mL	of	cold	MACS	buffer	was	added	to	each	15	mL	tube	before	the	 tubes	were	 centrifuged	 (300	 x	g,	 5	min).	 The	 supernatant	was	 removed	 and	discarded,	and	the	pellets	resuspended	each	in	80	μL	cold	MACS	buffer	and	20	μL	of	anti-biotin	microbeads	(Miltenyi,	Cat	no.	130-090-485)	per	3	x	106	cells.	Cells	were	then	incubated	at	4	oC	for	15	min,	after	which	1	mL	of	cold	MACS	buffer	was	added	to	each	15	mL	tube,	followed	by	centrifugation	(300	x	g,	5	min).	The	supernatant	was	 removed	 and	 discarded,	 and	 the	 pellets	 resuspended	 in	 500	 μL	 cold	MACS	buffer.		
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The	 cells	 were	 separated	 with	 the	 Miltenyi	 autoMACS	 Pro	 Separator	 (Miltenyi	Biotec,	 Cat	 no.	 130-092-545)	 with	 positive	 selection	 program	 (Figure	 2.2).	 The	collected	 cells	 were	 centrifuged	 (300	 x	 g,	 5	min),	 the	 supernatant	 removed	 and	discarded,	and	the	pellets	resuspended	in	1	mL	E3	medium	(108)	with	10	μM	ROCK	inhibitor.	The	cells	were	counted	and	then	plated	on	Matrigel-coated	wells	of	a	6	well	tissue	culture	plate	(6wp)	at	105	cells/	cm2	in	2	mL	E3	medium	(with	10	μM	ROCK	inhibitor	for	the	first	24	h	only)	then	maintained	in	an	incubator	at	37	oC,	5%	(vol/vol)	CO2.	The	E3	medium	was	changed	daily	thereafter	until	the	ROR1+	cells	were	confluent.			
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Figure 2.2 AutoMACS separation of ROR1+ cells from lens cell mixture 
The heterogeneous cell mixture containing ROR1+ cells was mixed with biotinylated ROR1 antibody then 
anti-biotin microbeads. The mixture was passed through a magnetized column that retained labelled cells. 
The non-labelled cells were collected and discarded. The magnet is deactivated then the ROR1+ cells are 
eluted and collected for culture. 	
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2.2.6 Cell culture on silk fibroin and chitosan films The	 procedure	 for	 mixing	 and	 casting	 chitosan	 films	 was	 adapted	 from	 (135).	Chitosan	 powder	 1.7	 %	 (by	 weight)	 (medium molecular weight, lot number 
MKBH1108V, average degree of acetylation, DA, of 24 % of monomer units and 
viscosity of 563 cP in 1 % acetic acid)	was	mixed	with	a	2	%	(by	weight)	acetic	acid	aqueous	 solution	 at	 room	 temperature	 (protected	 from	 light	 by	 wrapping	 in	aluminium	foil)	for	5	days.	The	dispersion	was	centrifuged	at	1076	×g	and	23	°C	for	1	h.	10	mL	aliquots	were	placed	in	a	9	cm	Petri	dish	and	dried	at	room	temperature	to	form	clear,	colorless	chitosan	films.	Briefly,	1	cm2	sections	of	chitosan	film	were	stirred	with	EDC-HCl	(3	mg,	3.13	mM),	NHS	(2	mg,	3.48	mM),	and	peptide	(RGDS,	1	mg,	0.46	mM)	in	PBS	then	placed	on	a	shaker	for	up	to	18	h	then	rinsed	with	PBS	and	ultrapure	water,	dried	and	stored	at	-20oC	(135).		The	silk	fibroin	(courtesy	of	Prof	Traian	Chirila,	Queensland	Eye	Institute,	Australia),	and	RGDS	grafted	chitosan	films	(with	a	maximum	of	5600	RGDS	peptide	units	per	nm2	(135)),	were	prepared	for	cell	culture	by	soaking	overnight	in	PBS,	coating	with	1	mg/mL	of	Matrigel	in	DMEM	and	exposing	to	UV	light	for	1	h	inside	the	biological	safety	cabinet.	The	silk	fibroin	was	treated	identically;	however,	it	did	not	tolerate	handling	 during	 this	 process	 and	 was	 eliminated	 from	 further	 testing.	 5	 x	 105	purified	ROR1+	cells	were	added	to	each	3mm	diameter	sections	of	chitosan	film,	incubated	at	37oC	for	30	min	or	until	cells	attached	to	chitosan	film,	then	E3	medium	was	 gently	 added	 to	 the	 culture	 vessel	 to	 submerge	 the	 chitosan	 films.	 Purified	ROR1+	 cells	 were	 cultured	 on	 chitosan	 films	 from	 at	 least	 three	 separate	differentiation	experiments	and	they	repeatedly	failed	to	attach	and	proliferate.		
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2.2.7 Harvesting ROR1+ cells and preparing aggregates  Briefly,	AggreWell	plates	(Stem	Cell	Technologies,	Cat	no.	27845)	were	prepared	as	per	 the	manufacturer’s	 instructions	 (141)	 before	 ROR1+	 cells	were	 collected	 via	TrypLE.	ROR1+	cells	were	seeded	into	the	AggreWell	plates	at	5	x	105	cells/well	and	aggregated	by	centrifugation	at	300	x	g,	5	min.	The	aggregates	were	cultured	in	the	AggreWell	plate	for	24-48	h,	then	collected	and	embedded	in	0.25%	(w/v)	agarose	in	M199	in	24	well	plates.	Aggregates	were	cultured	in	Stage	3	medium	for	up	to	28	days,	with	daily	medium	changes. 
2.2.8 Agarose embedding of ROR1+ aggregates A	 1	 L	 glass	 beaker	 containing	 400	 mL	 of	 sterile	 water,	 magnetic	 stirrer	 and	thermometer	was	covered	with	aluminium	foil.	Two	aliquots	of	9	mL	M199	(Gibco	Life	Technologies,	Cat	no.11150-059)	was	added	to	two	separate	15	mL	tubes	and	placed	in	the	beaker.	The	agarose	suspension	was	prepared	by	placing	0.5	g	agarose	powder	(Amresco	Agarose	1,	Cat	no.	0710-500G)	 in	50	mL	M199	medium	before	heating	 in	 a	microwave	oven.	To	make	0.25%	 (w/v)	 agarose,	 3	mL	of	1%	 (w/v)	agarose	was	added	to	the	pre-warmed	9	mL	M199,	in	the	biosafety	cabinet.	The	15	mL	 tubes	were	 returned	 to	 a	 beaker	 of	 37oC	water	before	harvesting	 the	ROR1+	aggregates	commenced.	The	agarose	did	not	exceed	37oC	at	the	time	of	embedding	to	 prevent	 the	 potential	 of	 heat	 exposure	 to	 change	 protein	 structure	 or	 gene	expression	of	the	aggregates.	
2.2.9 Harvesting and embedding ROR1+ aggregates  The	aggregates	in	the	AggreWell	plate	were	gently	triturated	with	a	2	mL	pipette	then	carefully	collected	and	placed	in	a	15	mL	tube.	Wells	were	washed	with	1	mL	E3	medium,	 the	 collection	process	 repeated	 and	 the	medium	added	 to	 the	 tubes	containing	the	aggregates.	The	aggregates	were	allowed	to	settle	via	gravity	for	10-20	min.	The	supernatant	was	carefully	removed	leaving	the	calculated	volume	in	the	bottom	of	 the	 tube	sufficient	 to	provide	50	μL	of	aggregates	 for	each	subsequent	desired	treatment.		
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A	similar	volume	of	PBS	was	placed	in	a	second	15	mL	tube	to	provide	a	visual	guide	to	 the	 final	 volume	 required	 in	 the	 aggregate-containing	 tube.	 To	 check	 the	efficiency	of	the	settling	process,	the	removed	supernatant	was	placed	into	a	35	mm	or	60	mm	dish	and	checked	under	the	microscope	for	aggregates.		The	 settled	 aggregates	were	 resuspended	 in	 the	 remaining	 volume	before	50	μL	aliquots	were	placed	 in	the	desired	number	of	24-well	plate	wells.	Once	this	was	done,	300	μL	of	0.25%	(w/v)	agarose	was	added	to	each	well.	When	the	0.25%	(w/v)	agarose	was	completely	gelled,	500	μL	of	Stage	3	medium	(DMEM:F12	containing	100	ng/mL	FGF2	and	20	ng/	mL	Wnt3a	 (R&D	Systems	Cat	no.	1324-WN/CF)	20	ng/mL)	was	added	to	each	well	on	top	of	the	0.25%	(w/v)	agarose.	The	cell	culture	medium	was	changed	daily	thereafter.	
2.2.10 Measuring light transmission and light focusing 
ability The	aggregates	were	assessed	at	various	times	during	the	culture	period	for	light	transmission	and	 light	 focusing	ability.	 Images	of	each	aggregate	were	taken	at	5	positions.	Using	a	light	microscope	and	accompanying	digital	camera	the	aggregates	were	brought	into	focus	and	an	image	taken	using	the	imaging	software	Q	Capture	Pro	v6	(Q	Imaging,	Brisbane,	Australia).	Noting	the	number	of	rotations	of	the	fine	focus	knob,	the	objective	was	moved	to	the	point	of	maximal	light	focus	and	another	image	 was	 taken.	 The	 objective	 was	 moved	 in	 the	 same	 direction	 for	 the	 same	number	of	turns	of	the	fine	focus	knob	and	another	image	taken.	The	objective	was	then	raised	to	midway	between	each	of	the	previously	taken	images	and	two	other	images	taken	(providing	5	images	in	total).	Measurements	of	light	transmitted	and	focal	point	intensity	were	obtained	using	the	quantification	function	of	Fiji	ImageJ	software,	 by	 quantifying	 approximately	 the	 central	 quarter	 diameter	 of	 the	aggregate,	and	a	similar	measurement	taken	from	the	surrounding	media.	The	data	were	 analysed	 using	 the	 Kolmogorov-Smirnov	 test	 for	 normal	 distribution	 then	subsequently	analysed	using	the	Student’s	t-test.			
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2.2.11 Mass spectrometry analysis of micro-lenses Minimal	 sized	 segments	 of	 0.25%	 (w/v)	 agarose	 containing	 micro-lenses	 were	mechanically	 separated	 from	 the	 remaining	 0.25%	 (w/v)	 agarose.	 The	 segments	were	 homogenized	 using	 a	micro-pestle	 (SSBio,	 Cat	 no.	 1005-39)	 in	 0.5%	 (w/v)	RapiGest	SF	(Waters,	Cat	no.	186001861)	on	ice	before	reduction	in	100	μL	of	5	mM	dithiothreitol	(Calbiochem)	in	50	mM	NH4HCO3	then	placed	in	a	heating	block	for	1	h	at	60	°C.	Samples	were	then	alkylated	with	100	μL	of	15	mM	iodoacetamide	at	room	temperature	for	1	h	then	200	ng	trypsin	(Promega,	Cat	no.	V5280)	in	75	mM	NH4HCO3	 added	 for	 protein	 digestion	 and	 placed	 in	 a	 heating	 block	 for	 16	 h,	 or	overnight,	at	37	°C.		The	peptides	were	purified	by	solid	phase	extraction	(SPE)	using	Waters	Oasis	HLB	cartridges	 (Waters,	 Cat	 no.	 186003908).	 The	 cartridges	were	washed	with	1	mL	acetonitrile	 (ACN)	 then	 0.1%	 (vol/vol)	 trifluoroacetic	 acid	 (TFA)	 placed	 into	 the	cartridge	to	condition	the	environment.	The	sample	was	acidified	by	adding	250	μL	0.4%	(vol/vol)	aqueous	TFA	to	neutralize	the	buffer	and	deactivate	the	trypsin,	then	loaded	into	the	extraction	cartridge.	Samples	were	washed	with	1	mL	0.1%	(vol/vol)	TFA	 to	 remove	 salts	 then	 1	 mL	 ultrapure	 water	 to	 remove	 aqueous	 soluble	unwanted	material	and	TFA.	Samples	were	eluted	with	500	μL	of	70%	(vol/vol)	ACN	to	 650	 μL	 low	 binding	 collection	 tubes	 (Simport,	 Cat	 no.	 T330-6LST).	 ACN	 was	evaporated	 from	 the	 collection	 tubes	 to	 dryness	 using	 rotational	 vacuum	concentrator	(Christ	RVC	2-25	CD	plus)	for	3	h.	15	μL	of	0.1%	(vol/vol)	formic	acid	was	 added	 to	 acidify	 peptide,	 rested	 for	 30	 min,	 triturated,	 then	 centrifuged	(Dynamica	Velocity	14R)	for	10	min	at	20	290	x	g.	 The	 formic	 acid	 solution	 containing	 the	peptides	was	 collected	 in	 glass	vials	 and	analyzed	 by	 LC-MS/MS	 using	 a	 nanoAcquity	 UPLC	 and	 Xeno	 QtoF	 mass	spectrometer	 (Waters)	 using	 a	 nanoelectrospray	 source	 implementing	 a	 glass	emitter	tip	which	tapers	to	10	µm	(New	Objective,	Woburn	MA).	The	analysis	was	carried	out	by	Dr	David	Harman.	The	MS/MS	data	files	were	analyzed	with	Mascot	Daemon	and	checked	with	SwissProt	database	with	Homo	sapiens-specific	searches.	
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2.2.12 Immunofluorescence analysis of micro-lenses Cultured	micro-lenses	were	fixed	within	the	surrounding	agarose	inside	the	24-well	plates	using	10%	(vol/vol)	neutral-buffered	formalin	(NBF)	(Sigma),	then	placed	on	a	rocker	for	up	to	48	h.	Afterwards,	the	NBF	was	removed	and	the	samples	washed	three	times	for	1	h	each	time	with	PBS.	The	24-well	plates	were	sealed	with	Parafilm	and	stored	at	4oC	until	processing.	Minimal	sized	segments	of	0.25%	(w/v)	agarose	containing	micro-lenses	were	mechanically	 separated	 from	 the	 remaining	0.25%	(w/v)	 agarose,	 embedded	 in	 2%	 (w/v)	 agarose	 and	 placed	 in	 tissue	 processing	cassettes.	 The	 samples	 were	 dehydrated	 in	 a	 Micro	 STP-120	 Tissue	 Processor	(Thermo	 Fisher	 Scientific)	 in	 50%	 (vol/vol),	 70%	 (vol/vol)	 and	 80%	 (vol/vol)	ethanol	for	60	min	each	then	95%	(vol/vol)	and	100%	(vol/vol)	ethanol	for	2	x	90	min	each,	xylene	for	3	x	90	min	then	paraffin	for	1	x	60	min	then	1	x	90	min.	Samples	were	manually	 embedded	 in	 paraffin	 and	 cut	 into	 5	 μm	 thick	 sections	 using	 an	Microm	HM325	microtome	before	being	mounted	on	glass	microscope	slides.	The	following	solutions	were	prepared	for	immunofluorescence	analysis.	0.1%	 (vol/vol)	BSA	 in	PBS:	2.3	mL	of	10%	 (vol/vol)	BSA	 (Miltenyi	Biotech)	was	placed	in	a	glass	measuring	cylinder	and	made	up	to	230	mL	with	PBS	(+Ca/+Mg).		10%	(w/v)	Tween20	stock	solution:	3	g	of	Tween	20	(Amresco,	Cat	no.	M147)	was	added	to	27	mL	of	PBS	(+Ca/	+Mg)	in	a	50	mL	tube	and	mixed	on	a	roller,	to	prevent	bubbles	forming.	Wash	buffer:	2.3	mL	of	10%	(vol/vol)	(Miltenyi	Biotech)	and	2.3	mL	of	10%	(w/v)	Tween20	was	placed	in	a	glass	measuring	cylinder	and	made	up	to	230	mL	with	PBS	(+Ca/+Mg).	
 59 
The	following	primary	antibodies	were	prepared	to	a	concentration	of	4	to	5	μg/mL	in	wash	buffer:	αA-crystallin	Rabbit	IgG	(Santa	Cruz,	Cat	no.	sc-22743),	β-crystallin	Rabbit	IgG	(Santa	Cruz,	Cat	no.	sc-22745),	γ-crystallin	Rabbit	IgG	(Santa	Cruz,	Cat	no.	 sc-22746)	 and	 Rabbit	 IgG	 control	 (Innovative	 research,	 Cat	 no.	 121266101).	Sections	to	be	stained	were	outlined	on	the	underside	of	the	slide	with	a	Stat	marker	(Statmark,	Trajan	Scientific)	before	slides	were	rehydrated	in	glass	Coplin	jars	with	35	mL	each	of	the	following	solutions	in	sequential	order:	10	dips	in	xylene	wash	then	immersed	2	x	10	min;	2	x	5	min	in	100%	(vol/vol)	ethanol;	1	x	5	min	in	95%	(vol/vol)	ethanol;	1	x	5	min	in	70%	(vol/vol)	ethanol;	1	x	5	min	in	50%	(vol/vol)	ethanol;	1	x	5	min	in	30%	(vol/vol)	ethanol;	1	dH2O	rinse;	2	x	5	min	in	wash	buffer.	Slides	were	then	placed	on	a	Teriwipe	and	the	Stat	marker	lines	visible	through	the	slide	 were	 used	 to	 guide	 separation	 of	 each	 section	 using	 hydrophobic	 solution	provided	by	a	Pap	Pen	(Trajan	Scientific).	Sections	were	blocked	with	approximately	100	 μL	 of	 10%	 (vol/vol)	 Normal	 Goat	 Serum	 (NGS)	 (Life	 Technologies,	 Cat	 no.	50062Z)	for	10	min	at	room	temperature,	after	which	the	NGS	was	tapped	off	onto	a	Kimwipe.	The	blocked	slides	were	placed	in	a	plastic	embedding	mould	inside	a	small,	 sealable	 container	 lined	 with	 water-dampened	 sponges	 to	 create	 and	maintain	a	humid	environment.	100	µL	of	diluted	primary	antibody	or	control	was	added	to	each	section.	The	container	was	sealed	and	placed	in	the	4oC	cool	room	overnight,	 after	 which	 the	 primary	 antibody	 solutions	 were	 removed.	 All	subsequent	steps	used	wash	buffer	0.1%	(vol/vol)	BSA	and	0.1	%	(w/v)	Tween	20	in	PBS	(+	Ca/+Mg):	100	µL	of	wash	buffer	was	added	to	each	section	for	2	×	10	min	then	slides	were	placed	in	35	mL	wash	buffer	in	Coplin	jar	for	10	min.	Diluted	goat	anti-rabbit	 AlexaFluor488	 (Invitrogen,	 Cat	 no.	 A11078)	 secondary	 antibody	was	diluted	 to	 1/1000	 in	 wash	 buffer	 and	 100	 µL	 was	 added	 to	 each	 section	 and	incubated	at	room	temperature	in	a	dark	cupboard	for	1	h.	The	secondary	antibody	was	then	removed	and	slides	washed	for	2	x	10	min	in	35	mL	in	wash	buffer	in	a	Coplin	jar.		
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Slides	were	then	placed	in	a	1/1000	dilution	of	the	nuclear	stain	DAPI	(Invitrogen,	Cat	no.	D3571)	in	wash	buffer,	in	a	foil-wrapped	Coplin	jar	for	10	min.	The	slides	were	 rinsed	 in	 35	mL	wash	 buffer	 in	 a	 foil-wrapped	 Coplin	 jar	 for	 10	min	 then	mounted	gently	dried	by	tapping	on	to	a	Kimwipe	then	mounted	with	DPX	solution	(Trajan	 Scientific,	 Cat	 no.	 1.00579.0500)	 before	 being	 imaged	 using	 a	 CKX41	microscope	with	an	Olympus	ORFLT50	camera	and	Q	Capture	Pro	6.	
2.2.13 Vx-770 toxicity assay Commencing	on	the	day	of	embedding,	ROR1+	aggregates	in	0.25%	(w/v)	agarose	were	treated	with	Stage	3	medium	with	either	dimethyl	sulfoxide	(DMSO)	(Sigma	Aldrich,	Castle	Hill,	Australia)	or	Vx-770	(Selleckchem,	Cat	no.	S1144)	in	the dose	range	between	200	and	2000	ng/mL.	DMSO	had	been	shown	not	to	cause	cataract	(142)	so	was	used	as	the	vehicle	for	dispersing	the	Vx-770	into	aqueous	medium.	Stock	solutions	were	made	for	each	dose	as	shown	in	Table	2.1.		
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Table 2.1 Vx-770 dose stock solutions 
	Aggregates	were	exposed	to	the	dose	of	Vx-770	for	up	to	28	days.	Light	focusing	and	light	transmittance	was	measured	at	regular	intervals	and	samples	were	collected	for	analysis	by	mass	spectrometry	at	days	7,	18	and	27,	as	described	above.		
Desired final 
concentration Vx-
770  
(ng/mL) 
dilution 
Vx-770 
: 
DMSO 
DMSO 
(μL) 
Vx-770 (2 mg/mL 
stock 
concentration) 
(μL) 
Vx770:DMSO 
added to 2mL stage 
3 medium  
( μL) 
0 0:1 50 0 2 
200 1:10 5 45 2 
500 1:4 12.5 37.5 2 
1000 1:2 25 25 2 
1500 3:4 37.5 12.5 2 
2000 1:0 0 50 2 
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2.3 Results 
2.3.1 Generation of purified ROR1+ LEC cultures To	 generate	 lens	 cells,	 a	 published	modification	 (Figure	 2.1)	 of	 the	 3-stage	 lens	differentiation	protocol	was	used	(108).	As	previously	reported,	the	initial	stages	of	this	protocol	generated	a	heterogeneous	mixture	of	cells	and	lentoids	(Figure	2.3A).	Dissociation	of	these	heterogeneous	cultures	at	approximately	day	16	was	followed	by	ROR1-based	MACS,	and	subsequent	culture	produced	a	homogeneous	population	of	LEC-like	cells	with	similar	morphology	(Figure	2.3B)	 to	human	PS	cell-derived	lens	cells	(108)	and	human	fetal	lens	cells	(143).	Purified	ROR1+	cells	were	cultured	until	confluence	in	a	published	medium,	E3,	shown	to	maintain	LEC-like	polygonal	morphology	(108).	
2.3.2 ROR1+ LEC aggregation to form thousands of teleost-
like lens cell masses Initial	attempts	made	during	the	early	experimental	phase	of	this	project	to	replicate	the	LEC	monolayer	and	subsequently	the	lens	vesicle	using	human	PS	cell-derived	lens	cells	were	ultimately	unsuccessful.	The	premise	was	to	culture	a	monolayer	of	LECs	on	peptide-grafted	chitosan	film	(functionalized	for	LEC	attachment)	(144)	or	a	 silk	 fibroin	membrane	 (145,146).	Ultimately,	 the	 silk	 fibroin	did	not	withstand	handling	 during	 Matrigel	 coating.	 The	 purified	 ROR1+	 cells	 did	 not	 attach	 or	proliferate	 sufficiently	 to	 the	RGDS-grafted	chitosan	 films	 (data	not	 shown)	 for	a	paired-explant	 type	 system	 to	 be	 a	 viable	 method	 in	 this	 case.	 Chitosan	 film	 is	biocompatible	and	remains	a	suitable	substrate	for	future	investigation	of	lens	cell	culture.	However,	work	to	improve	surface	and	peptide	grafting	homogeneity,	and	biodegradability,	 was	 outside	 the	 focus	 of	 this	 thesis.	 Therefore,	 a	 different	approach	 to	 forming	 the	 lens-like	 tissue	 in	 vitro	 was	 investigated,	 specifically,	identifying	lens	formation	in	other	species	and	determining	whether	these	may	be	adapted,	or	mimicked,	for	use	with	human	PS	cell	derived	lens	cells.	
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To	mimic	 the	ball-like	masses	of	 early	 teleost	 lens	development,	 the	ROR1+	 cells	were	aggregated	using	commercially	available	AggreWell	plates	(Figure	2.4A).	The	resultant	aggregates	were	fairly	uniformly-sized	spheroids	of	approximately	400-500	tightly	packed	cells,	roughly	80-100	µm	in	diameter	(Figure	2.4B).	These	ball-like	 aggregates	 appeared	 less	 dark	 under	 phase	 imaging	 than	 the	 surrounding	agarose	3D	growth	environment	(Figure	2.4C).	This	simple	method	yielded	up	to	1200	 aggregates	 per	 well	 of	 the	 AggreWell	 plate.	 By	 using	 several	 wells	simultaneously,	 production	 of	 tens-of-thousands	 of	 similarly-sized	 ROR1+	aggregates	could	be	generated.	The	agarose	gel	3D	growth	environment	supported	the	aggregates	and	effectively	prevented	their	attachment	to	the	culture	plastic	or	to	each	other	(Figure	2.4C).			
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Figure 2.3 Generation of purified cultures of ROR1+ lens epithelial cells 
(A) human PS cell culture in Stage 2 medium on Day 13 showing variable-sized lentoids (arrowheads; 
ultimately lost from culture) and polygonal cells (asterisk, inset), comparable to those described in the 
published protocol (90,108). (B) Homogeneous population of tightly-packed polygonal LEC-like cells (inset; 
magnified) obtained via ROR1-based MACS. Scale bars (A, B) 200 µm 	
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Figure 2.4 Aggregation of ROR1+ lens epithelial cells 
(A) Schematic diagram showing the aggregation and embedding step of ROR1+ cells into ball-like masses 
before initiation of Stage 3 of the lens cell differentiation protocol (90,108). (B) Aggregated ROR1+ cells 
(arrows) within micro-wells of an AggreWell plate showing the majority of input cells were incorporated 
into clearly-defined aggregates. (C) Low magnification image of ROR1+ aggregates (arrowheads) 
embedded in agarose. Scale bars (B) 200 µm; (C) 1 mm 	
B C 
A 
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2.3.3 Maturation of aggregates into micro-lenses On	day	1	of	aggregate	culture	(i.e.,	the	day	of	embedding),	spheroidal	aggregates	of	ROR1+	cells	(Figure	2.5A-E)	transmitted	less	light	than	the	surrounding	3D	growth	environment	 (Figure	 2.5K).	 At	 this	 stage,	 the	 aggregates	 also	 had	 minimal	 light	focusing	ability,	indicating	the	spheroidal	shape	alone	was	insufficient	for	marked	focusing	ability	(Figure	2.5C).		After	24	days	in	stage	3	culture,	the	ROR1+	cell	aggregate	had	developed	increased	light	 transmission	as	well	as	 the	ability	 to	 focus	 light,	with	 tracking	of	 individual	aggregates	showing	a	marked	increase	in	both	light	transparency	(Figure	2.5A	vs	F)	and	focusing	ability	(Figure	2.5C	vs	H).	Light	transmission	measurements	indicated	that	by	approximately	day	24	of	aggregate	culture,	the	light	transmission	ability	of	the	aggregates	had	reached	that	of	the	background	culture	medium	(Figure	2.5F,	K).	These	data	were	 found	 to	normally	distributed	with	 the	Kologorov-Smirnov	 test,	therefore	the	parametric	T-test	was	applied.	The	light	focusing	ability	of	the	micro-lenses	also	increased	markedly	over	this	period	(Figure	2.5H,	L).	 
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2.3.4 Human PS cell-derived micro-lenses express LF cell 
proteins Analysis	by	mass	spectrometry	demonstrated	that	LF	cell	crystallin	proteins	became	increasingly	expressed	at	later	stages	of	culture;	α-crystallins	were	present	in	early	culture	and	LF	cell-like	β-crystallins	were	detected	by	approximately	day	1	(Figure	2.6	and	Table	2.2).	This	detection	of	α-	and	β-crystallins	by	mass	spectrometry	was	supported	by	immunofluorescence	on	micro-lenses	at	day	24	(Figure	2.7).	The	α-	and	β-crystallins	were	expressed	uniformly	across	the	micro-lens	sections	(Figure	2.7A,	B).	Whilst	γ-crystallin	was	not	detected	by	mass	spectrometry	on	the	samples	tested,	 immunofluorescence	 showed	 variable	 expression	 across	 the	 micro-lens	(Figure	2.7C).	Immunofluorescence	analysis	confirmed	the	presence	and	location	of	crystallin	proteins	detected	during	mass	spectrometry	analysis.	Analyses	of	other	lens	 epithelial	 cell	 markers	 were	 outside	 the	 scope	 of	 this	 thesis.	 These	 data	indicated	 that	 purified	 ROR1+	 LECs,	 when	 aggregated,	 can	 be	 induced	 to	 form	thousands	 of	 uniform	 ball-like	 masses	 that	 develop	 light	 transmission	 and	 light	focusing	as	they	increase	expression	of	LF	cell	crystallin	proteins.		
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Figure 2.5 Aggregated ROR1+ cells develop into light-transmitting micro-lenses with significant light 
focusing capacity 
(A-E) Light microscopy images taken at identical incremental distances below the aggregates on day 3 
post-aggregation demonstrated the aggregates transmitted less light than the culture medium (A) and 
possessed limited capacity to focus light (C). (F-J) Micro-lenses on day 27 typically transmitted equivalent 
levels of light compared to the culture medium (F) and focused light to an intense point (H). (K) 
Quantification of the increase in light transmission of the aggregates relative to the background on day 3 
and day 24. (L) Quantification of the increase in light focusing ability on day 3 and day 24. The 
representative images in Figure 2.5A-E and Figure 2.5F-J were the taken from the same aggregate at the 
different time points indicated. Scale bar (A-J) 50 µm 
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Table 2.2 Micro-lens proteins identified by mass spectrometry 
Analysis by mass spectrometry identified α-crystallin in micro-lenses cultured in stage 3 medium at days 
7, 18 and 27; LF cell β-crystallins were identified at approximately day 18 and day 27. The number of 
peptides identified and the percent sequence coverage for example crystallin peptides are indicated (e.g. 
5, 28%, respectively). 
Lens proteins 
identified Day 7 Day 18 Day 27 
CRYAA 1, 6% 8, 30% 8, 35% 
CRYBB1 - 5, 28% 9, 34% 
CRBA1 - - 1, 6% 
CRBA4 - - 4, 13% 		
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Figure 2.6 Representative mass spectrometry data demonstrating micro-lenses express α-and β-
crystallin proteins 
 (A, B) MS/MS analysis showed 35% sequence coverage of CRYAA at day 18 (A), with example raw data 
peptide identification of sequence TVLDSGISEVR (A, underlined and B). (C, D) MS/MS analysis showed 39% 
sequence coverage of CRYBB1 at day 27 (C), with example raw data peptide identification of sequence 
ASASATVAVNPGPDTK (C, underlined and D). 
 
A 
B 
C 
D 
 71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Cultured micro-lenses express LF cell-like crystallins 
(A-C, E-G) Immunofluorescence staining showed uniform expression of αA-crystallin (A) and β-crystallin 
(B) after culture in Stage 3 media for 24 days. Expression of γ-crystallin was detected by day 24 (C). Control 
immunofluorescence image showing non-specific staining (D). The corresponding images of DAPI-stained 
nuclei are shown (E-H). Scale bar 50 µm 	
A 
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2.3.5 Treatment with Vx-770 reduced micro-lens function To	 test	whether	 the	micro-lens	 system	was	 suitable	 for	 drug	 toxicity	 assays,	 the	developing	 micro-lenses	 were	 exposed	 to	 clinically	 relevant	 doses	 of	 Vx-770.	Aggregates	were	dosed	in	the	range	of	0	ng/mL	(vehicle	only)	to	2000	ng/mL	which	corresponds	 to	 the	 range	 of	 clinical	 doses	 of	 Vx-770	 in	 pediatric	 cystic	 fibrosis	patients	(137).	After	23	days,	the	vehicle-only	treated	micro-lenses	(Figure	2.8A	to	E)	had	developed	light	transmission	and	focusing	capability	similar	to	the	functional	micro-lenses	 generated	 in	 stage	 3	media	 only	 (Figure	 2.5F	 to	 J).	 In	 contrast,	 the	ROR1+	 aggregates	 treated	 with	 500	 ng/mL	 and	 higher	 doses	 of	 Vx-770	 did	 not	develop	into	functioning	micro-lenses.	Light	microscopy	observation	showed	that	these	ROR1+	aggregates	lost	the	initial	defined-edge	and	did	not	develop	the	same	level	of	light	transmission	and	focusing	ability	that	micro-lenses	treated	with	lower	doses	did	(Figure	2.8K,	L).	Quantification	of	these	observations	showed	a	significant	difference	between	the	relative	light	transmission	and	relative	focal	intensity	of	the	vehicle-only	treated	aggregates	compared	to	treatments	of	500	ng/mL	and	higher.			
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Figure 2.8 Development of micro-lens function is reduced by treatment with Vx-770 
(A to E) Representative images of a micro-lens treated with 0 ng/mL Vx-770 (vehicle only control ) for 23 
days of culture shows the aggregate developed similar light transmission (A) and focusing capability (C) to 
untreated micro-lenses (i.e., compared with Figure 2.5C). (F to J) Representative images of a micro-lens 
treated for 23 days with 2000 ng/mL Vx-770 shows the aggregate lost the defined-edge and did not 
develop light transmission (F) or focusing ability (H). (K, L) The response to Vx-770 was dose-dependent; 
micro-lenses developed light transmission ability (K) and focusing ability (L) with control and 200 ng/mL 
treatments but did not at doses at or above 500 ng/mL (*p < 0.05; day 23 of culture). Scale bar 50 µm 	
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2.4 Discussion 
2.4.1 Mimicking cross species development for 3D tissue 
regeneration Previous	attempts	to	produce	mammalian	micro-lenses	in	vitro	included	harvest	of	LEC	monolayers	via	rat	lens	explants	which	were	then	paired	to	mimic	the	hollow	lens	 vesicle	 (125).	 That	 rat	 lens	 explant	 pair	 lens	 model	 demonstrated	 light	transmission	and	focusing	ability	(125).	Furthermore,	a	cataract	developed	in	this	model	 (125),	 indicating	 that	 such	 a	 lens	 model	 could	 be	 used	 for	 investigating	cataractogenesis.	Chitosan	film	is	biocompatible	and	bacteriostatic	and	remains	a	suitable	substrate	for	future	investigation	of	lens	cell	culture.	However,	the	ROR1+	LECs	did	not	attach	and/or	proliferate	well	on	the	initial	chitosan	preparations.	As	the	 research	 required	 to	 improve	 the	 surface	 homogeneity	 and	 peptide	 grafting	efficiency	 was	 outside	 the	 focus	 of	 this	 thesis,	 an	 alternative	 approach	 was	investigated.	 Animal	models	 have	 been	widely	 used	 in	 cataract	 studies	 (22)	 and	while	 they	 are	 useful,	 they	 are	 not	 human	 tissue.	 Indeed,	 there	 are	 differences	between	 the	 cell	membrane	 composition	 of	 human	 lenses	 and	 those	 from	 other	animals	(147)	as	well	as	growth	characteristics,	for	example,	human	lenses	have	a	greater	proportion	of	growth	in	the	pre-natal	period	compared	to	other	species	(69).	Moreover,	 expression	 of	 γ-crystallin	 homologs	 between	 species	 differs;	 human	expression	of	γS-crystallin	differs	from	fish	(γM-crystallin),	bovine	(γB,	γE-crystallin	)	and	mouse	(γ-crystallin)	(71,148).		
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Differences	 in	 lenses	 between	 species	 are	 not	 limited	 to	 differences	 in	 crystallin	expression	 and	 cell	 membrane	 composition.	 They	 also	 include	 the	 physical	variations	of	lens	organogenesis.	For	example,	mammalian	lenses	arise	from	a	LEC-lined	 vesicle	 and	 teleost	 lenses	 arise	 from	 a	 ball-like	 mass	 of	 LECs.	 By	 forming	mammalian	cells	 into	a	 teleost-inspired	ball-like	mass,	human	micro-lenses	were	produced	from	ROR1+	cells.	Thus,	mimicking	the	physical	pathway	of	 teleost	 lens	development	 enabled	 production	 of	 uniform,	 light	 transmitting,	 light	 focusing	human	micro-lens	tissue.	Developmental	studies	of	other	species	and	their	organ	development	pathways	may	provide	further	insight	and	alternate,	perhaps	simpler,	means	 of	 producing	 human	 PS	 cell-derived	 organoids	 for	 other	 (i.e.,	 non-lens)	tissues	in	the	future.	
2.4.2 Human micro-lenses can be produced in vitro in large 
quantities  The	original	3-stage	process	to	differentiate	lens	cells	from	human	PS	cells	(90)	was	capable	of	producing	hundreds-to-thousands	of	 lentoid	bodies	during	the	3-stage	process.	As	the	lentoids	were	lost	to	the	culture	medium,	they	were	unable	to	have	light	 focusing	or	 light	 transmitting	capacity	measured,	and	 they	were	not	 readily	available	 for	 downstream	 analysis.	 Consequently,	 lentoids	 produced	 via	 the	unmodified	3-stage	differentiation	method	have	had	relatively	limited	utility	as	an	
in	vitro	human	lens	model	to	study	lens	development	or	cataract.		
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Attempts	to	improve	on	this	human	PS	cell	lens	model	have	been	recently	published	(91,93).	 Fu	 and	 colleagues	 (91)	 produced	 tens-to-hundreds	 of	 lentoids	 that	possessed	magnification	 ability.	These	 lentoids	had	properties	 indicative	of	 their	lens-like	nature,	(91)	including	an	increase	in	relative	expression	of	LF	cell	genes	
CRYBB2	and	CRYG.	However,	this	“fried-egg”	process	of	generating	these	lentoids	is	complex	and	labour	intensive,	and	therefore,	unsuitable	for	large-scale	production	of	lens	organoids.	Moreover,	the	electron	microscopy	images	obtained	from	these	“fried-egg”	lentoids	in	the	literature	revealed	internal	structures	that	appear	to	less	closely	 resemble	 that	 of	 a	 normal	 lens	 compared	 to	 the	 ROR1+	 micro-lenses	produced	here.	The	micro-lenses	produced	during	these	experiments	demonstrated	characteristics	of	LF	cells.	 Indicators	of	terminal	LF	cell	differentiation	included	a	peripheral	LEC	monolayer	degrading	nuclei,	and	development	of	LF	cell	membrane	interdigitations	 (108).	 These	 physical	 characteristics	 of	 micro-lenses	 generated	within	 our	 laboratory	 were	 examined	 by	 electron	 microscopy	 and	 published	(Appendix	A)	along	with	data	generated	by	myself	and	others,	however	analysis	of	these	images	were	undertaken	by	others	and	thus	excluded	from	this	thesis	(108).		A	more	useful	 system	of	 large-scale	human	 lens	organoids,	 for	 example	 for	drug	screening	assays,	requires	generation	of	tens-to-hundreds	of	thousands	of	uniform	lens-like	tissues	with	clearly	demonstrated	lens	functional	abilities.	The	ROR1	cell-based	system	described	here	can	produce	such	numbers	of	uniform	micro-lenses	in	a	highly	controlled	manner.	These	lentoids	are	not	randomly	lost	from	the	culture	system,	 and	 they	 express	 known	 lens	 fiber	 cell	 proteins.	 In	 addition	 to	 the	 drug	screening,	these	properties	of	the	ROR1+	micro-lenses	could	be	used	specifically	for	studying	human	lens	development.	These	micro-lenses	derived	from	human	PS	cells	could	facilitate	insight	into	the	key	time	points	that	α-,	β-	and	γ-crystallin	commence	and	cease	expression	in	the	lens,	and	how	this	correlates	with	development	of	light	focusing	ability.	This	could	facilitate	investigation	of	the	molecular	aspects	of	gene	regulatory	 networks	 and	 their	 controls,	 organelle	 loss	 and	 nuclear	 degradation	during	lens	development,	which	have	typically	only	been	observed	in	non-human	models.	These	human	PS	cell-derived	micro-lenses	are	 the	 first	of	 their	kind	that	provide	 large	amounts	of	 in	vitro	human	 lens	 tissues	suitable	 for	 investigation	of	development	and	for	drug	toxicity	screening.	
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2.4.3 Clinical utility of the micro-lenses Changes	 in	 light	 transmission	 and	 light	 focusing	 during	micro-lens	 development	were	 measured	 in	 the	 micro-lens	 generation	 system	 described	 in	 this	 chapter.	Initially	aggregated	ROR1+	cells	did	not	transmit	light	at	a	greater	intensity	than	the	background	medium.	However,	after	culture	with	growth	factors	 that	 induced	LF	cell	 development,	 the	 aggregates	 transmitted	 greater	 light	 than	 previously,	 and	similar	 to	 that	 of	 the	 background	 medium.	 Likewise,	 light	 focusing,	 a	 key	characteristic	 of	 the	 lens,	 was	 an	 important	 indicator	 that	 the	 micro-lenses	generated	possessed	functional	properties	similar	to	larger	in	vivo	lens	tissue.	The	intensity	of	the	light	focused	was	quantified,	and	therefore,	able	to	form	the	basis	of	an	assay	to	investigate	light	focusing	changes	related	to	cataract	and	drug	response.		Cataracts	are	opacities	that	cause	light	scatter	in	the	lens,	thereby	impairing	vision	by	 reducing	 light	 transmission	 to	 the	 retina.	The	cystic	 fibrosis	drug	Vx-770	was	chosen	to	model	cataract	formation	in	the	micro-lenses	as	it	is	suspected	of	causing	cataract	 in	 young	 cystic	 fibrosis	 patients	who	 have	 received	 the	 drug	 (133,134).	Diminished	vision	resulting	from	childhood	cataract	has	long-term	social,	emotional	and	developmental	consequences	 (10).	An	 inability	 to	develop	 light	 transmission	and	light	focusing	ability,	conceptually	similar	to	cataract,	was	induced	by	exposing	aggregates	to	500	ng/mL	and	higher	doses	of	Vx-770	from	the	beginning	of	micro-lens	 culture.	 These	 data	 suggest	 that	 the	 micro-lens	 system	 may	 be	 useful	 for	defining	the	molecular	mechanisms	responsible	for	the	formation	of	human	cataract	thought	to	be	caused	by	Vx-770.	More	generally,	the	micro-lenses	could	reduce	the	necessity	for	animal-based	toxicity	testing	of	emerging	drugs	(22).	The	 micro-lenses	 could	 also	 provide	 a	 platform	 for	 further	 discovery	 of	 the	molecular	 mechanisms	 of	 cataract	 caused	 by	 other	 risk	 factors,	 such	 as	hyperglycemia	 (34)	 and	 smoking	 (149).	 For	 example,	 protein	 ageing	 and	subsequent	instability	(150)	as	well	as	glycation	of	crystallins	(21,72)	are	postulated	risk	factor	mechanisms	of	cataract	formation	that	could	be	investigated	using	the	micro-lens	 system.	 Similarly,	 changes	 in	 protein	 aggregation	 or	 other	 post-translational	 modifications	 (PTMs),	 such	 as	 methylation	 (42,151),	 could	 be	identified.	 In	 turn,	 this	 could	 lead	 to	 investigation	 and	 development	 of	 potential	patient-specific	(i.e.,	risk	factor-specific)	anti-cataract	drugs.	
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2.4.4 Limitations of the agarose 3D growth environment  The	relative	simplicity	of	the	micro-lens	system	means	that	other	laboratories	can	replicate	the	differentiation,	purification,	aggregation	and	embedding	protocols	and	generate	 many	 thousands	 of	 micro-lenses	 for	 cataract	 research.	 The	 3D	 growth	environment	 that	 agarose	 provided	 had	 several	 advantages	 for	 use	 as	 a	 first	embedding	medium.	Agarose	is	inexpensive	and	readily	available;	it	did	not	require	specialized	 equipment	 in	 order	 to	 produce	 the	 growth	 environment	 for	 the	aggregates.	The	micro-lenses	were	supported	in	a	3D	growth	environment	allowing	the	 spheroidal	 shape	 of	 the	 micro-lens	 to	 be	 maintained;	 this	 is	 difficult,	 if	 not	impossible	to	maintain	if	aggregates	are	attached	to	a	hard	culture	plastic	surface	(that	also	doesn’t	reflect	normal	lens	biology).	Moreover,	agarose	is	transparent	at	the	 concentrations	 used	 here	 and	 thus	 allowed	 for	 quantification	 of	 light	transmission	and	light	focusing	of	the	micro-lenses.		In	 addition	 to	 these	 positive	 physical	 properties,	 the	 agarose	 gel	 conceivably	provided	a	concentration	gradient	for	the	growth	factors	FGF2	and	Wnt3a	to	mimic	the	 lens	 forming	gradient	 thought	 to	occur	 in	vivo	 (75).	Nevertheless,	 there	were	some	inherent	difficulties	being	certain	that	this	was	the	case.	The	pore	sizes	within	the	agarose	gel	were	almost	certainly	heterogeneous	and	it	could	not	be	certain	that	a	 growth	 factor	 concentration	 gradient	was	 established.	 Additionally,	 harvesting	and	processing	 of	 the	micro-lenses	 in	 the	manner	 described	 did	 not	 ensure	 that	situational	polarity	was	maintained,	therefore	the	effect	of	a	theoretical	gradient	by	establishing	a	definite	apical-basal	relationship	between	LECs	and	LF	cells	could	not	be	determined.		
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Despite	the	success	of	generating	these	micro-lenses	in	agarose,	there	were	some	limitations	 associated	 with	 this	 system.	 Firstly,	 the	 0.25%	 (w/v)	 agarose	 has	 a	narrow	 temperature	 range	 at	 which	 it	 will	 gel.	 This	 means	 that	 the	 timing	 of	aggregate	harvesting	and	embedding	must	perfectly	align	with	the	point	at	which	the	gel	has	cooled	and	the	precise	temperature	cannot	be	measured	at	the	time	of	embedding	due	to	sterility	issues	that	might	contaminate	the	culture.	If	left	too	long,	the	 aggregates	 risk	 clumping	 together	 or	 attaching	 to	 the	 culture	 surface	 before	embedding	 is	 completed.	 Secondly,	 obtaining	 the	 correct	 temperature	 for	embedding	 is	 challenging:	 if	 the	 agarose	 is	 too	 hot,	 it	 can	 cause	 damage	 to	 the	aggregates,	for	example,	by	changing	the	tertiary	structure	of	α-crystallin,	or	gene	expression	 of	 the	 aggregates.	 If	 it	 is	 too	 cool	 it	 before	 embedding	 has	 been	completed.	Thirdly,	there	is	a	risk	of	contamination	during	the	embedding	process	when	heating/cooling	the	agarose.	Further	drawbacks	of	the	agarose	system	include	difficulty	harvesting	micro-lenses	for	 physical	 investigations.	 Both	 imaging	 by	 electron	 microscopy	 and	immunofluorescence	required	thin	sections	of	tissue	to	be	cut	using	a	microtome.	The	micro-lenses	are	very	small	and	are	held	in	a	relatively	large	volume	of	the	3D	growth	environment.	This	made	harvesting	and	sectioning	difficult	as	there	were	often	few,	if	any,	micro-lenses	present	in	any	given	section,	making	the	sectioning	process	 extremely	 time-consuming.	 Increasing	 the	 ratio	 of	 micro-lenses	 to	 3D	growth	environment	would	be	advantageous.	This	can	be	achieved	in	either	of	two	ways.	 The	 first	way	 is	 to	 increase	 the	 number	 of	micro-lenses	 in	 the	 3D	 growth	environment	(which	risks	individual	micro-lenses	not	receiving	sufficient	nutrients	or	 growth	 factors).	A	 second	approach	would	be	 to	 remove	part	or	 all	 of	 the	3D	growth	 environment	 once	 the	 developmental	 phase	 is	 complete	 but	 without	damaging	or	compromising	the	structural	or	molecular	integrity	of	the	micro-lenses.		A	3D	growth	environment	that	retains	the	positive	properties	of	the	current	system,	i.e.,	transparent,	permeable	and	able	to	withstand	handling	during	long-term	culture	with	daily	medium	changes	 -	but	 is	degradable	 for	harvesting	 the	micro-lenses	–	would	be	more	desirable.	The	following	chapter	assesses	agarose	alternatives	in	an	attempt	to	further	improve	the	utility	of	the	micro-lens	system.		
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Chapter 3 Evaluation of an alternative 3D 
growth environment for micro-
lenses and assessment of ROR1-
enriched vs purified ROR1+ cell 
derived micro-lenses 
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3.1 Introduction 
3.1.1 Alternative 3D growth environments  As	described	 in	Chapter	2,	 the	production	of	 thousands	of	human	PS	cell-derived	light-focusing	micro-lenses	was	achieved	by	culturing	aggregated	ROR1+	cells	in	an	agarose	3D	growth	environment.	While	this	approach	was	effective,	two	key	steps	are	subject	to	significant	challenges	that	could	 limit	routine	application:	handling	difficulties	with	the	use	of	the	agarose	for	embedding	the	micro-lenses,	and	time,	labour	and	financial	costs	associated	with	production	of	ROR1+	cells.	Firstly,	as	previously	mentioned,	agarose	supported	production	of	the	micro-lenses	by	ensuring	that:	they	were	rarely	in	contact	with	each	other	or	the	plastic	ware;	they	were	not	lost	or	damaged	during	daily	media	changes	for	several	weeks;	and	that	 nutrients	 and	 lens-inducing	 growth	 factors	 were	 accessible	 to	 ROR1+	 cells.	Secondly,	some	challenges	were	noted	including	the	narrow	working	temperature	range	during	embedding,	the	risk	of	contamination,	and	difficulties	upon	harvesting	the	 micro-lenses	 for	 downstream	 analysis.	 Due	 to	 these	 difficulties,	 alternative	commercially-available	physiologically	relevant	hydrogel	3D	growth	environments	were	investigated	(152).	Desirable	properties	of	an	alternative	to	agarose	include	rapid	setting	(so	that	aggregates	would	remain	suspended),	a	working	temperature	range	 close	 to	 37oC,	 permeability	 to	 nutrients	 and	 growth	 factors,	 mechanical	stability	to	allow	routine	media	changes	and	the	ability	to	dissociate	the	embedding	material	to	harvest	micro-lenses	for	downstream	analysis.		
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The	options	available	were	to	either	produce	an	artificial	extracellular	matrix,	the	most	promising	of	which	was	a	complex	 to	produce	poly(ethylene	glycol)	 (PEG)-peptide	conjugated	hydrogel	(153,154),	or	to	use	a	commercially-available	hydrogel	product.	A	disulphide-containing	poly(ethylene	glycol)	diacrylate	(PEGSSDA)	based	hydrogel	may	be	cross-linked	(polymerised)	in	the	presence	of	hyaluronic	acid	to	produce	a	hydrogel	(155).	Non-enzymatic	dissolution	of	the	hydrogel	matrix	takes	place	by	dissociation	of	the	thiol	bonds	in	the	presence	of	N-acetyl-L-cysteine	(155).	To	 both	 maintain	 the	 simplicity	 of	 the	 micro-lens	 system	 and	 ensure	 testing	 of	quality	controlled	agarose	alternatives,	only	commercially-available	products	were	assessed	 here.	 Numerous	 commercially-available	 hydrogel	 matrices	 have	 been	reported	to	replicate	the	tissue	growth	environment	allowing	culture	of	tissues	in	a	3D	 growth	 environment	 (152).	 Three	 commercially	 available	 hydrogel	 products	were	 identified	 as	 potentially	 possessing	 the	 desirable	 criteria	 (Table	 3.1);	 the	hyaluronic	 acid-based	 hydrogels	 HyStemC	 (Sigma	 Aldrich),	 HyStem	 +	 PEGSSDA	(BioTime	 Inc)	and	 the	peptide-based	HydroMatrix	 (Sigma	Aldrich).	Each	of	 these	products	 has	 different	 attributes	 for	 handling	 (mixing	 the	 hydrogel	 precursors)	during	the	initiation	of	polymerisation,	at	the	embedding	stage,	as	well	as	hydrogel	concentration	and	dissociation,	thus	allowing	assessment	of	a	broad	range	of	these	parameters	in	order	to	try	and	identify	an	improved	hydrogel	for	culturing	micro-lenses.	
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3.1.2 More efficient generation of micro-lenses In	addition	to	finding	an	alternate	3D	growth	environment,	the	methods	associated	with	 purification	 of	 the	 ROR1+	 cells	 retained	 some	 inefficiencies.	 While	 the	published	 E3	 Medium	 stimulates	 proliferation	 of	 the	 ROR1+	 cells	 (108),	 large	numbers	 of	 cells	 are	 lost	 through	 the	 (relatively	 time	 and	 cost	 intensive)	MACS	procedure.	In	assessing	ways	to	further	improve	the	cost	effectiveness	of	obtaining	ROR1+	cells,	it	was	noticed	that	the	cell	filtration	step	immediately	prior	to	antibody	staining	resulted	in	significant	enrichment	of	ROR1+	cells	(on	average	80%)	(108).	This	 raised	 the	 possibility	 that	 the	 time	 and	 cost	 of	 MACS	might	 be	 avoided	 to	generate	enriched	(but	not	pure)	populations	of	ROR1+	cells	for	laboratory	(but	not	clinical)	applications.	Accordingly,	this	chapter	investigates	possible	improvements	to	 micro-lens	 production	 by	 culturing	 aggregates	 of	 ROR1-enriched	 cells	 in	alternative	 growth	 environments	 such	 as	 agarose	 or	 commercially-available	hydrogels.			
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3.2 Methods 
3.2.1 Reagents and consumables General	 cell	 culture	 reagents	 and	 consumables	 were	 as	 described	 in	 2.2.1.	Additionally,	 the	 following	 reagents	 were	 used	 in	 the	 following	 experiments:	HyStemC	with	 PEGSSDA	 linker	 kit	 (comprising	 EsiBio	 PEGSSDA	 0.5	mL,	 HyStem	Glycosil,	 HyStem	 Gelin-S	 and	 Degassed	 (DG)	 water)	 (EsiBio,	 Alameda	 CA,	 USA),	HydroMatrixTM	 (Sigma	 Aldrich,	 Castle	 Hill	 NSW,	 Australia),	 N-acetyl-L-cysteine	(Sigma-Aldrich,	Cat	no.	A7250-5G).	
3.2.2 Human PS cell and ROR1+ cell culture  Human	PS	cell	culture	methods	used	were	as	described	in	2.2.2.	Differentiation	to	heterogeneous	 populations	 containing	 lens	 cells	 was	 performed	 as	 described	 in	2.2.3,	up	to	and	including	the	40	μm	cell	filtration	step.	After	that,	the	ROR1-enriched	cells	were	cultured	until	confluent	in	E3	medium	(i.e.,	approximately	7	days	from	filtration)	as	described	for	the	purified	ROR1+	cells.		
3.2.3 Commercial hydrogel assessment The	 selected	 hydrogels	 were	 prepared	 in	 accordance	 with	 the	 manufacturer’s	specifications	and	variations	in	the	final	hydrogel	concentration	concomitant	with	published	data	(156,157).	The	assessment	process	for	the	hydrogels	is	outlined	in	Figure	3.1.	
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Figure 3.1 Assessment of commercial hydrogels for culture of ROR1-enriched aggregates 
Flow chart depicting the process to determine whether hydrogels met the requirements for culture and 
retrieval of ROR1-enriched aggregates. A number of candidate products were selected on the basis that 
they would support 3D culture of cells. The products could be used at varying concentrations, therefore 
the hydrogel concentration at which stiffness properties were compatible with daily media changes was 
determined. The suitable candidate hydrogel or hydrogels were dissociated following the recommended 
method. The hydrogel or hydrogels that met the selection criteria were selected for further testing with 
human PS cell aggregates and finally compared to 0.25% (w/v) agarose with ROR1-enriched aggregates.  	
select commercial hydrogels
optimise hydrogel 
concentration for 
withstanding media changes
assess hydrogel dissociation
determine which hydrogel 
for further testing
proof-of-principle 
assessment of hydrogel with 
human PS cell aggregates
comparison of hydrogel with 
0.25% agarose
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	The	commercial	hydrogels	were	prepared	as	described	(Table	3.2,	Table	3.3)	and	subjected	to	the	following	assessment	criteria	(Table	3.1)	to	determine	suitability	for	use	with	aggregated	lens	cells.	The	assessment	criteria	were	scored	as	per	Table	3.1.	The	methods	used	to	test	key	hydrogel	properties	were:	
Time	to	polymerise:	after	mixing	the	hydrogel	components,	each	well	was	checked	every	5	min	to	determine	whether	the	hydrogel	had	set.	Hydrogel	polymerisation	time	(at	room	temperature)	over	20	to	25	min	was	unsuitable	due	to	the	potential	for	aggregates	to	settle	out	of	the	hydrogel	solution	and	attach	to	the	culture	plastic.	
Rigidity	 of	 hydrogel:	 the	 rigidity	 was	 checked	 by	 tilting	 the	 24	 well	 plate	 and	observing	the	level	line	at	the	top	of	the	hydrogel	to	determine	whether	the	hydrogel	had	set,	then	gently	shaking	the	24	well	plate	while	observing	under	the	microscope.	The	rigidity	was	checked	immediately	after	gelling	and	24	h	later,	after	medium	had	been	removed.		
Hydrogel	resistance	after	contact:	the	hydrogel	surface	was	touched	with	a	blue	tip	 and	 it	was	 noted	whether	 the	 blue	 tip	 penetrated	 and/or	 left	 a	mark	 on	 the	hydrogel	surface.		
Ability	 to	 change	 media:	 to	 simulate	 cell	 culture	 medium,	 500	 μL	 of	 PBS	 was	layered	 on	 top	 of	 a	 hydrogel	 without	 aggregates	 and	 incubated	 overnight.	 The	following	 day,	 500	 μL	 of	 PBS	was	 removed	 and	 it	 was	 noted	whether	 complete	medium	removal	occurred	without	disrupting	the	hydrogel	surface.		
Hydrogel	 dissociation:	 each	 hydrogel	 was	 dissociated	 according	 to	 the	manufacturer’s	protocol.	Once	the	hydrogels	were	dissociated,	they	were	removed	and	placed	 into	an	adjacent	well	of	a	24	well	plate	 to	assess	 the	completeness	of	dissociation	by	noting	number	and	size	of	hydrogel	lumps	present,	if	any.		
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Table 3.1 Assessment criteria for commercial hydrogel 
Score Time to polymerise 
Rigidity of 
hydrogel 
Ability to change 
medium without 
disrupting gel 
integrity 
Dissociation of 
hydrogel 
+++ 5-10 min most rigid gel integrity retained complete dissociation in <30 min 
++ 10 – 20 min moderately rigid some disruption to edges of gel 
complete dissociation 
in 30-60 min 
+ 20-30 min rigid significant disruption to edges of gel 
incomplete or partial 
dissociation requiring 
additional PBS rinse 
- >30 min or did not set did not gel 
could not change 
media without 
removing significant 
amount of gel 
no dissociation or 
incomplete 
dissociation after 
additional PBS rinse 
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3.2.4 Preparation of HydroMatrix Peptide Cell Culture 
Scaffold HydroMatrix	has	a	pH	of	2.5	when	 in	aqueous	 solution	 (1%	w/v).	Consequently,	isometric	(20%	w/v)	sucrose	is	needed	to	be	added	to	the	cells	to	be	encapsulated	to	 protect	 the	 cells	 until	 physiological	 pH	 is	 obtained.	 Therefore,	 a	 20%	 (w/v)	sucrose	solution	was	prepared	by	weighing	2.0	g	of	sucrose	and	dissolving	in	10	mL	of	sterile	water.	The	sucrose	solution	was	filter	sterilized	using	a	0.22	μm	filter	and	syringe.		To	 generate	 the	 hydrogel,	 0.5	 mL	 sterile	 water	 was	 added	 to	 lyophilized	HydroMatrix	 in	 an	 attempt	 to	 make	 a	 2%	 (w/v)	 solution.	 The	 product	 did	 not	disperse	 in	 this	 volume;	 therefore,	 a	 further	 0.5	 mL	 was	 added.	 Reconstituted	HydroMatrix	was	kept	on	ice	to	prevent	premature	formation	of	the	hydrogel.	Gels	were	prepared	at	1%	(w/v),	0.5%	(w/v)	and	0.25%	(w/v)	concentration,	according	to	the	manufacturers	protocol,	in	separate	wells	of	a	24-well	plate	as	per	Table	3.2.	Then	500	μL	PBS	(+Ca/+Mg)	was	added	to	each	well	and	gently	triturated,	to	initiate	gelation.	The	24	well	plate	was	placed	in	an	incubator	at	37oC,	5%	(vol/vol)	CO2,	and	checked	at	5	min	intervals	for	gelling	as	described	in	Table	3.4.		
Table 3.2 Preparation of HydroMatrix hydrogel 
 
 0.25% 0.5% 1% 
HydroMatrixä stock solution (1% w/v) 75 uL 150 uL 300 uL 
water 225 uL 150 uL - 
20% (w/v) sucrose solution 50 uL 50 uL 50 uL 	Dissociation	of	the	HydroMatrix	hydrogel	was	achieved	by	trituration	with	a	P1000	micropipette	until	liquefied,	as	per	manufacturer’s	instructions.		
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3.2.5 Preparation of HyStem + PEGSSDA hydrogel HyStemC	 +	 PEGSSDA	 was	 prepared	 at	 concentrations	 recommended	 by	 the	manufacturer	 and	at	 those	 found	 in	 literature	 for	 recovery	of	 cells	 for	metabolic	analysis	 and	 CHiP	 sequencing	 (158).	 Following	 the	manufacturer’s	 protocol,	 the	Glycosil,	and	Gelin-S	solution	were	prepared	by	dissolving	the	lyophilized	solid	in	1	mL	 de-gassed	 (DG)	water,	 using	 a	 syringe.	 The	 vials	 were	 vortexed	 then	 placed	horizontally	on	a	shaker	for	approximately	40	min	for	the	solids	to	disperse.	250	μL	DG	water	was	added	to	PEGSSDA	to	make	a	2x	concentrated	solution.	All	solutions	were	 kept	 on	 ice	 and	 used	 within	 2	 h	 of	 reconstitution.	 Gelin-S,	 Glycosil	 and	PEGSSDA	were	combined	directly	in	wells	of	a	24	well	plate	in	the	amounts	stated	in	 Table	 3.3.	 The	 HyStem+PEGSSDA	 solutions	 were	 triturated	 and	 immediately	placed	in	the	incubator	at	37oC,	5%	(vol/vol)	CO2,	and	checked	at	5	min	intervals	for	setting	as	described	in	section	3.2.3.	
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Table 3.3 Preparation of HyStem + PEGSSDA hydrogel 
The HyStem + PEGSSDA was prepared to produce a range of concentrations. The amounts of each 
component used for each concentration is indicated below. 
 softest standard stiffest 
HyStemC with 
PEGSSDA A B C D E F 
gel concentration 
(%)(w/v) 0.25 0.5 1 2 4 6 
Glycosil (μL) 120 120 120 120 120 100 
Gelin-S (μL) 120 120 120 120 120 100 
DG water (μL) 56.25 52.5 45 30 0 0 
PEGSSDA (μL) 2x 
concentrate 3.75 7.5 15 30 60 100 
 
 For	dissociation	of	the	HyStem	+	PEGSSDA	hydrogels,	5.45	g	N-acetyl-L-cysteine	was	dissolved	in	100	mL	sterile	M199	medium,	filtered	with	a	0.22	μm	filter	and	stored	in	sterile	tubes	at	-30oC.	Following	this,	1	mL	of	40	mM	N-acetyl-L-cysteine	solution	was	added	to	the	top	of	each	hydrogel	in	the	24-well	plate	and	gently	triturated	8	times.	The	plate	was	incubated	at	37oC,	5%	(vol/vol)	CO2	for	1	h.	Dissociation	was	confirmed	by	triturating	with	a	2	mL	pipette.	If	intact	hydrogel	was	observed,	then	the	plate	was	incubated	a	further	30	min.	Once	the	hydrogel	was	dissociated,	it	was	removed	 and	 placed	 in	 1	 well	 of	 a	 24-well	 plate	 to	 assess	 the	 completeness	 of	dissociation	by	inspecting	for	presence	and	size	of	hydrogel	lumps	present,	if	any.	
3.2.6 Assessment of human ES cell aggregates in hydrogel The	 HyStem	 +	 PEGSSDA	was	 trialled	 at	 4%	 (w/v)	 and	 6%	 (w/v),	 for	 culture	 of	human	ES	cell	line	CA1	aggregates.	The	CA1	aggregates	were	prepared	as	per	2.2.6,	replacing	ROR1+	cells	with	CA1	human	PS	cells.	The	harvested	aggregates	(section	2.2.6)	were	embedded	in	300	μL	HyStem	+	PEGSSDA	in	a	24-well	plate.			
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3.2.7 Time course assessment of ROR1-enriched 
aggregates  
 
 
Figure 3.2 Experiment plan for assessing micro-lenses derived from ROR1-enriched cell populations 
Three biological replicate cultures of ROR1-enriched cells were separately aggregated and plated in each 
0.25% (w/v) agarose and hydrogel before being exposed to Stage 3 medium (90) for 35 days. Aggregates 
were harvested on or near day 3, day 7, day 14 and day 35 for analysis by mass spectrometry. Light 
transmission and light-focusing measurements were taken on or near days 3, 7, 14, 28 and 36. Aggregates 
were harvested on or near day 3, day 7, day 14 and day 35 for analysis by mass spectrometry.  	
ROR1-
enriched 
aggregates
mass 
spectrometry
light 
focusing
light 
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3.2.7.1 Preparation of ROR1-enriched lens cell aggregates in 
HyStem + PEGSSDA hydrogel ROR1-enriched	lens	cell	aggregates	were	prepared	as	described	in	section	2.2.6,	and	plated	 in	 between	 2	 layers	 of	 6%	 (w/v)	 HyStem	 +	 PEGSSDA	 with	 added	concentrated	E3	medium	mixture.	The	E3	concentrate	was	added	 to	yield	a	 final	concentration	 in	 the	 hydrogel	 equivalent	 to	 E3	ROR1+	 cell	maintenance	medium	(section	2.2.5).	GelinS	and	Glycosil	were	made	with	1	mL	of	DG	water.	PEGSSDA	was	made	to	a	2x	concentration	with	250	μL	DG	water.	The	GelinS,	Glycosil	and	PEGSSDA	hydrogel	 components	 were	 mixed	 to	 prepare	 a	 6%	 (w/v)	 solution	 (Table	 3.3).	GelinS	and	Glycosil	were	combined	in	a	tube	with	E3	super	concentrated	medium,	then	PEGSSDA	added.	Immediately	upon	addition	of	PEGSSDA,	a	150	μL	base	layer	was	added	to	the	required	wells	of	a	24-well	plate.	The	24-well	plate	was	placed	in	an	 incubator	 for	60	min	at	37°C,	5%	(vol/vol)	CO2	 in	order	 for	 the	base	 layer	 to	completely	polymerise.		ROR1-enriched	aggregates	were	prepared	as	described	in	section	2.2.6.	Using	a	2	mL	 pipette,	 aggregates	 were	 removed	 from	 the	 AggreWell	 and	 left	 in	 a	 loosely	capped	15	mL	tube	to	settle	for	15	min.	The	supernatant	was	removed	and	40	μL	containing	aggregates	was	added	to	each	well,	on	the	surface	of	the	base	layer.		A	second	batch	of	GelinS,	Glycosil	and	PEGSSDA	hydrogel	components	were	mixed	to	prepare	a	6%	(w/v)	solution	(Table	3.3).	GelinS	and	Glycosil	were	combined	in	a	tube	with	E3	super	concentrated	medium,	then	PEGSSDA	added.	Immediately	upon	addition	of	PEGSSDA,	200	μL	was	added	to	the	wells	of	the	24	well	plate	to	make	a	200	μL	overlay	of	hydrogel.	The	overlay	method	was	described	in	(129)	whereby	one	layer	was	allowed	to	set	then	a	second	hydrogel	and	cell	layer	added.	The	24	well	plate	was	placed	in	an	incubator	for	30	min	at	37°C,	5%	(vol/vol)	CO2	to	allow	the	top	layer	to	polymerise.	500	μL	of	Yang	stage	3	(DMEM:F12	medium	with	100	ng/mL	FGF2	and	20	ng/	mL	Wnt3a)	medium	was	added	to	each	well,	on	top	of	the	hydrogel.		
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3.2.7.2 Preparation of ROR1-enriched aggregates in 0.25% 
agarose ROR1-enriched	 aggregates	were	 prepared	 as	 described	 in	 section	 2.2.5.	 Samples	were	collected	on	or	near	days	3,	7,	14	and	36	for	analysis	by	mass	spectrometry.	The	 collected	 samples	 of	 0.25%	 (w/v)	 agarose	 containing	 the	 aggregates	 were	homogenized	with	a	plastic	micro-pestle,	directly	in	a	1.5	mL	Eppendorf	tube	before	addition	of	Rapi-Gest	 and	 the	 samples	were	processed	 for	mass	 spectrometry	as	described	 in	 section	 2.2.11.	 Light	 focusing	 and	 light	 transmittance	 data	 were	collected	as	described	in	section	2.2.10.		 	
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3.3 Results 
3.3.1 Assessment of commercial hydrogel physical 
properties  As	a	first	step	to	determining	the	suitability	of	the	3	hydrogels	for	micro-lens	culture,	their	 aggregation	 and	 dissociation	 characteristics	 were	 assessed.	 Dissociation	 of	HyStemC	 hydrogel	 required	 overnight	 incubation	 with	 collagenase	 or	hyaluronidase,	raising	the	possibility	that	this	would	result	in	significant	changes	in	micro-lens	gene	expression	profile	(a	key	desired	downstream	analysis	method	for	micro-lens	samples).	On	this	basis,	HyStemC	was	excluded	from	further	assessment.	According	to	manufacturer	instructions,	both	HyStem	+	PEGSSDA	and	HydroMatrix	were	 recommended	 for	 use	 at	 varying	 concentrations.	 Therefore,	 the	 hydrogel	concentration	at	which	stiffness	properties	of	these	two	hydrogels	were	compatible	with	daily	media	changes	was	determined.	As	aggregates	take	approximately	10-20	min	to	settle	in	a	15	mL	tube	immediately	after	harvesting	from	the	AggreWell	plates	25	min	was	 chosen	 as	 the	maximal	 allowed	 time	 for	 hydrogel	 setting.	HyStem	+	PEGSSDA	at	concentrations	at	or	lower	than	3%	(w/v)	did	not	set,	either	at	all,	or	within	the	25	min	timeframe.	HydroMatrix	did	not	gel	at	any	concentration	within	the	25	min	timeframe.	Accordingly,	HydroMatrix	was	excluded	from	further	testing,	as	were	concentrations	of	HyStem+	PEGSSDA	below	3%	(w/v).		As	 micro-lens	 culture	 currently	 requires	 daily	 medium	 changes,	 both	 HyStem+	PEGSSDA	 concentrations	 were	 assessed	 for	 their	 mechanical	 strength	 via	 their	ability	to	withstand	medium	changes.	This	involved	looking	under	the	microscope	and	tilting	or	shaking	the	24	well	plate	in	addition	to	determining	whether	a	blue	tip	would	 leave	 a	mark	 on	 the	 surface	 of	 the	 polymerized	 hydrogel.	 The	 6%	 (w/v)	HyStem	+	PEGSSDA	hydrogel	withstood	media	change	without	loss	or	damage	to	the	gel,	and	the	4%	(w/v)	HyStem	+	PEGSSDA	hydrogel	sustained	some	minor	loss	and	damage	during	the	test	media	change.					
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Table 3.4 Assessment of commercial hydrogels at varying concentrations 
The hydrogels were assessed according to the criteria described in (3.2.3). 
		
 HyStem + PEGSSDA HydroMatrix 
hydrogel 
% (vol/vol) 
0.25 0.5 1 2 3 4 6 0.25 0.5 1 
  Time taken 
to polymerise 
(min) 
>45 >45 >45 >45 >45  25 10 >30  >30 >30 
Rigidity of 
hydrogel 
day 0 
- - - - + ++ +++ - - - 
Rigidity of 
hydrogel 
day 1 
- - - - - + ++ - - - 
Ability to 
change 
media 
without 
disrupting 
hydrogel 
integrity 
- - - - + + ++ - - - 
Dissolution 
of hydrogel - - - - ++ ++ +++ - - - 
Proceed to 
further 
testing 
no no no no no yes yes no no no 
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An	 additional	 desirable	 hydrogel	 property	 is	 the	 capacity	 to	 easily,	 quickly	 and	cleanly	 dissociate	 and	 release	 the	 micro-lens	 tissues.	 This	 would	 facilitate	downstream	 analyses	 such	 as	 mass	 spectrometry	 and	 gene	 expression	 analysis	without	 interference	 by	 matter	 from	 the	 growth	 environment	 and	 decrease	 the	sectioning	time	required	for	immunofluorescence	or	electron	microscopy	analysis.	Therefore,	the	final	physical	parameter	tested	involved	the	ease	of	dissociation	of	the	hydrogels.	To	simplify	the	cost	and	time	required	for	this	testing,	ROR1-enriched	cell	aggregates	were	initially	omitted	from	the	testing.	Based	on	the	rigidity	testing,	only	the	4%	and	6%	(vol/vol)	HyStem	+	PEGSSDA	were	tested	for	dissociation	using	
N-acetyl-L-cysteine.	This	assessment	showed	that	both	concentrations	of	HyStem	+	PEGSSDA	dissociated	after	 incubation	and	 trituation	with	N-acetyl-L-cysteine.	On	the	 basis	 of	 these	 data,	 4%	 and	 6%	 (vol/vol)	 HyStem	 +	 PEGSSDA	 were	 the	commercially	available	hydrogels	chosen	for	subsequent	experiments.	
3.3.2 Assessment of human PS cell aggregates in hydrogel To	test	the	permeability	of	the	4%	and	6%	(w/v)	HyStem	+	PEGSSDA	of	hydrogels	for	embedding	aggregates,	a	pilot	test	using	human	PS	aggregates	was	performed	(as	 they	did	not	 require	 the	 lengthy	3-stage	differentiation	prior	 to	aggregation).	Embedding	human	PS	cell	aggregates	in	4%	(w/v)	HyStem	+	PEGSSDA	resulted	in	aggregates	settling	from	the	gel	and	attaching	to	the	culture	plastic.	Attachment	of	aggregates	to	the	culture	plastic	was	undesirable	for	the	production	of	micro-lenses,	therefore	 4%	 (w/v)	 HyStem	 +	 PEGSSDA	 was	 deemed	 unsuitable	 for	 culture	 of	aggregates.	 In	 contrast,	 the	human	PS	 cell	 aggregates	 embedded	 in	6%	hydrogel	remained	suspended	in	the	hydrogel.	As	the	6%	(w/v)	HyStem	+	PEGSSDA	hydrogel	withstood	media	changes,	inhibited	aggregate	attachment	to	the	culture	surface	and	enabled	survival	in	culture,	for	at	least	24	h,	of	the	human	PS	cell	aggregates,	the	6%	(w/v)	HyStem	+	PEGSSDA	was	assessed	 to	have	 the	most	 suitable	properties	 for	continuing	with	the	time	course	experiments	using	ROR1-enriched	cells.		
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3.3.3 Comparison of hydrogel and 0.25% agarose with 
ROR1-enriched cell aggregates In	 order	 to	 adequately	 compare	 the	 6%	 (w/v)	 HyStem	 +	 PEGSSDA	 hydrogel	 to	agarose	 for	 micro-lens	 culture,	 aggregates	 of	 ROR1-enriched	 cells	 (rather	 than	MACS-purified	ROR1+	cells)	were	embedded	in	both	3D	growth	environments	and	cultured	 in	 parallel.	 Three	 biological	 replicate	 experiments	 were	 completed	 and	compared	under	the	same	incubation	conditions	and	media	changes.	The	aggregates	and	 micro-lenses	 were	 assessed	 using	 light	 microscopy	 to	 measure	 light	transmission	and	focusing,	and	by	mass	spectrometry	to	compare	the	development	of	crystallin	proteins	in	each	3D	growth	environment.	The	morphology	of	the	ROR1-enriched	cells	obtained	directly	after	40	μm	filtering	and	 no	 MACS	 displayed	 a	 homogeneous	 distribution	 of	 polygonal	 shaped	 cells,	consistent	 with	 the	 phenotype	 of	 purified	 ROR1+	 cells	 (Figure	 3.3)	 and	 primary	human	fetal	LECs	(143).	Furthermore,	no	spontaneous	appearance	of	lentoids	was	noted	using	E3	Medium	(108)	prior	to	aggregate	formation	(similar	to	ROR1+	cell	cultures).		
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Figure 3.3 ROR1-enriched cells are morphologically similar to ROR1+ cells 
Day 7 (A) ROR1-enriched cells in a confluent monolayer appear homogeneous and possess the polygonal 
lens epithelial cell phenotypically similar to purified ROR1+ cells (B) (Figure 2.3). Scale bar 50 µm 	
A 
 
B 
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 The	day	after	embedding,	the	appearance	of	the	aggregates	in	HyStem	+	PEGSSDA	was	similar	to	those	in	agarose.	The	aggregates	in	both	3D	growth	environments	at	this	early	stage	had	low	light	transmission	compared	to	their	respective	3D	matrices	(Figure	3.6,	Figure	3.7).	In	some	instances,	this	included	dead	cells	surrounding	the	aggregates	as	previously	noted	(108).	Strikingly,	there	was	a	sharp	decline	in	the	number	of	intact	aggregates	by	the	third	day	after	embedding	in	HyStem	+	PEGSSDA.	The	 previously	 defined-edged	 aggregates	 had	 lost	 edge	 definition	 and	 formerly	aggregated	cells	appeared	to	detach	from	one	another	(Figure	3.4B,	E,	G).	By	day	7	(Figure	 3.4F)	 no	 aggregates	 in	 HyStem	 +	 PEGSSDA	 remained	 intact.	 This	 loss	 of	aggregates	 was	 repeatable,	 and	 was	 observed	 in	 all	 three	 biological	 replicate	experiments	 performed	 using	 HyStem	 +	 PEGSSDA	 (Figure	 3.4G).	 Ultimately,	 the	HyStem	+	PEGSSDA	cultured	ROR1-enriched	aggregates	were	discarded	on	day	7	after	 embedding	 as	 there	 were	 no	 viable	 aggregates	 remaining	 by	 that	 time.	Consequently,	 no	 further	 analyses	 were	 able	 to	 be	 performed	 on	 the	 HyStem	 +	PEGSSDA	 aggregates.	 In	 contrast,	 the	 majority	 of	 ROR1-enriched	 aggregates	cultured	 in	 agarose	 retained	 their	 defined	 edges	 throughout	 the	 culture	 period	(Figure	3.4A-C).	Furthermore,	 these	aggregates	were	typically	not	surrounded	by	dead	cells.	
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Figure 3.4 ROR1-enriched aggregates did not survive in HyStem + PEGSSDA hydrogel 
(A-C) ROR1-enriched aggregates embedded in 0.25% agarose at day 1 (A), day 3 (B) and day 7 (C) retained 
defined edges throughout the culture period indicative of live cells being present up to (and beyond) day 
7 (C). (D-F) ROR1-enriched aggregates embedded in HyStem + PEGSSDA hydrogel at day 1 had defined 
edges. By day 3, the aggregates appeared as clusters of dead cells (E, arrowheads, inset) and aggregate 
loss continued through to day 7 (F). (G) The loss of aggregates over this time was significant at each time 
point, with an almost total loss of aggregates in hydrogel by day 7, p<0.05. Scale bar 100 µm 
B 
A 
C 
D 
E 
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3.3.4 Aggregated ROR1-enriched cells developed lens-like 
properties, earlier than ROR1+ purified micro-lenses The	ROR1-enriched	aggregates	developed	lens-like	properties	in	the	same	manner	seen	with	the	purified	ROR1+	micro-lenses.	By	day	28,	the	light	transmission	of	the	micro-lens	had	at	least	reached	that	of	the	surrounding	medium	(Figure	3.6K).	The	light	 transmission	 and	 light	 focusing	 data	were	 analysed	 using	 the	 Kolmogorov-Smirnov	 test	and	were	 found	 to	be	normally	distributed	 then	analysed	using	 the	Student’s	t-test.	In	some	cases	it	was	higher,	likely	due	to	the	size	of	the	aggregates	causing	 a	 focusing	 effect	 beginning	when	 the	micro-lens	 periphery	was	 in	 focus.	Additionally,	by	day	28	the	ROR1-enriched	micro-lenses	had	developed	significant	focusing	ability	(Figure	3.6L).		Interestingly,	 by	 7	 days	 after	 embedding,	 the	 agarose-cultured	 ROR1-enriched	aggregates	had	started	to	develop	light	transmission	levels	close	to	the	surrounding	culture	medium	(Figure	3.4B,	C	and	Figure	3.7K).	This	was	earlier	than	the	purified	ROR1+	 aggregates	 described	 in	 Chapter	 2,	 where	 the	 light	 transmission	 reached	background	 levels	 by	 day	 24	 in	 culture	 (Figure	 2.5).	 Additionally,	 by	 day	 7,	 the	ROR1-enriched	aggregates	had	developed	obvious	light-focusing	(Figure	3.7L),	also	much	earlier	than	the	micro-lenses	derived	from	purified	ROR1+	cells	in	Chapter	2.	In	addition	to	noting	the	faster	development	of	light	transmission	and	light	focusing,	the	 ROR1-enriched	 aggregates	 were	 observed	 to	 develop	 irregular	 protrusions	around	day	14	of	culture	(Figure	3.5).	Light	microscopy	showed	that	in	some	cases	the	protrusions	appeared	to	mask	the	defined	edges	of	the	micro-lens	(Figure	3.6F	and	G).	
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Figure 3.5 ROR1-enriched micro-lenses developed protrusions  
Light microscopy images showed that ROR1-enriched cell aggregates had clearly defined edges at day 3 
(A). On day 14 there was evidence of formation of small protrusions on some aggregates (arrowhead, B). 
By day 28 numerous aggregates had formed protrusions (arrowheads, C). The majority of micro-lenses 
had formed protrusions by day 36. Day 28 micro-lenses retained their defined-edge core regardless of 
protrusion development (E-H). Protrusions were variable in size and position relative to the micro-
lens.  Scale bar (A-H) 100 μm 	
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Figure 3.6 Aggregated ROR1-enriched cells develop micro-lens properties 
Light microscopy images taken at increasing distances below the aggregates (A to E) on day 3 of culture 
show the initial low light transmission properties of the aggregates (A) and inability to focus light (C). (B 
to E) By day 28, the agarose-embedded ROR1-enriched micro-lenses transmitted light at least equal to 
the surrounding culture medium (F) and also had developed significant light-focusing ability (H). (K) 
Developing micro-lenses initially transmitted less light relative to the background medium at day 3, then 
more by day 28 (p<0.05). (L) The micro-lenses gain light focusing ability (position 3) and transmitted 
increased light (position 1) at day 28 compared to day 3 of culture and the surrounding culture medium. 
Scale bar 50 µm 	
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Figure 3.7 ROR1-enriched aggregates focus light 7 days after embedding in agarose  
Light microscopy images taken at incrementally increasing distances below the aggregates (A to E) on day 
3 of culture showed the initial low light transmission properties of the aggregates (A) and inability (C) to 
focus light. (F to J). By day 7, the micro-lens transmitted more light (F) and became able to focus light to 
a point (H). (K) Developing micro-lenses initially transmitted less light relative to the background medium 
at day 3, then equal to the background from day 7 onwards (p<0.05). (L) By day 7, the micro-lenses gain 
light focusing ability (position 3) and could transmit similar levels of light compared to the background 
culture medium (position 1). Scale bars (A-J) 50 μm 	
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3.3.5 Aggregated ROR1-enriched cells expressed crystallin 
proteins To	assess	 the	molecular	 changes	occurring	 in	 the	ROR1-enriched	aggregates,	 the	presence	 and	abundance	of	 lens	proteins	was	 ascertained	by	mass	 spectrometry	(Figure	3.8,	Figure	3.9).	β-crystallin	was	detected	at	all	time	points,	suggesting	that	immature	 LF-like	 cells	 were	 present	 in	 the	 ROR1-enriched	 lens	 cell	 culture.	 In	contrast,	micro-lenses	at	day	8	from	purified	ROR1+	cells	did	not	express	β-crystallin	(Section	2.3.4).	The	mass	spectrometry	analysis	also	revealed	a	trend	of	increasing	sequence	coverage	of	 the	crystallin	proteins	with	 increasing	culture	 time	(Figure	3.8)	–	suggesting	the	abundance	of	CRYAA,	CRYBA1,	CRYBA4,	CRYBB2,	and	CRYBB3	significantly	increased	during	the	culture	of	the	ROR1-enriched	cell	aggregates.		Notably, CRYGC	that	is	normally	present	at	high	concentrations	(>400	mg/mL)	in	the	lens	nucleus	(formed	during	the	pre-natal	lens	development	period)	(159)	was	identified	 in	 the	 ROR1-enriched	micro-lens	 samples	 taken	 at	 days	 7,	 14	 and	 36.	Additionally,	CRYGS	was	detected	in	the	later	stages	of	culture.	Together,	detection	of	the	β-	and	γ-crystallins	indicated	that	mature	LF-like	cells,	similar	to	those	found	in	the	lens	nucleus,	were	present	in	the	ROR1-enriched	aggregates	but	at	earlier	tie-points	compared	to	micro-lenses	derived	from	purified	ROR1+	cells.			
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Figure 3.8 Sequence coverage of lens proteins identified by mass spectrometry 
All proteins had greater sequence coverage on day 36 than day 3. All identified crystallins demonstrated 
a greater sequence coverage at day 36 than on day 3 after embedding. The increase in sequence coverage 
was significant (asterisk) for CRYAA, CRYBA1, CRYBA4, CRYBB2, and CRYBB3 (p<0.05). Interestingly, CRYGC 
was detected from day 7 onwards. 	
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Figure 3.9 Proteins identified in ROR1- enriched micro-lenses by mass spectrometry 
(A) MS/MS analysis showed 30% sequence coverage of CRYAA at day 36, with (B) example raw data 
peptide identification of sequence TVLDSGISEVR (A, underlined). (C) MS/MS analysis showed 89% 
sequence coverage of CRYBB1 at day 7, with example raw data peptide identification sequence 
ASASATVAVNPGPDTK (C, underlined). 
C 
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D 
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3.4 Discussion 
3.4.1 Evaluation of agarose and hydrogel 3D growth 
environments This	chapter	aimed	to	further	improve	the	culture	parameters	of	the	ROR1-based	micro-lens	system.	Desirable	properties	of	an	embedding	material	were	identified	as	permeability	to	nutrients	and	growth	factors,	polymerization	at	37oC,	mechanical	strength	and	the	ability	to	dissociate	to	release	micro-lenses	with	minimal	potential	alteration	 of	 transcription.	 Evaluation	 of	 3	 commercially-available	 hydrogels	identified	 6%	 HyStem	 +	 PEGSSDA	 as	 the	 only	 one	 with	 this	 range	 of	 required	properties.	 Despite	 this	 testing,	 including	 overnight	 assessment	 of	 CA1	 cell	aggregates,	6%	HyStem	+	PEGSSDA	did	not	support	longer-term	survival	of	ROR1-enriched	aggregates.	This	 failure	of	 the	HyStem	+	PEGSSDA	occurred	despite	 identical	 incubation	and	media	conditions	used	for	the	embedded	aggregates	set	up	and	cultured	alongside	the	 HyStem	 +	 PEGSSDA	 aggregates.	 The	 manufacturer’s	 highest	 recommended	concentration	was	4%	(w/v);	however,	this	hydrogel	was	successfully	used	at	6%	(w/v)	 for	 3D	 culture	 of	 stromal	 cell	 spheroids	 (158).	 The	 6%	 (w/v)	 HyStem	 +	PEGSSDA	 was	 the	 only	 hydrogel	 concentration	 that	 met	 the	 mechanical	requirements	for	daily	media	changes;	however,	the	permeability	of	the	hydrogel	to	nutrients	 and	 growth	 factors	 may	 have	 been	 reduced,	 potentially	 due	 to	 a	 high	degree	of	cross-linking	within	the	gel.	In	other	hydrogel	systems,	in	particular	the	PEG-peptide	based	hydrogels,	cells	can	have	the	ability	to	locally	break	down	the	gel	structure	by	the	action	of	matrix	metalloproteinase	(MMP),	allowing	contraction	of	the	 hydrogel	 to	 allow	 cell	 expansion	 (153,154,160).	 Restriction	 of	 aggregate	expansion	or	lack	of	access	to	growth	factors	in	the	HyStem	+	PEGSSDA	hydrogel	are	potential	causes	of	the	aggregates’	failure	to	develop	micro-lens	characteristics.	
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3.4.2 ROR1-enriched cells produced light-focusing micro-
lenses at an early time point  ROR1-enriched	cells	appeared	to	be	a	phenotypically	homogeneous	population	of	cells,	phenotypically	similar	to	purified	ROR1+	cells.	Despite	the	failure	of	the	6%	HyStem	 +	 PEGSSDA	 to	 support	micro-lens	 development,	 the	 agarose-based	 data	demonstrates	 that	 ROR1-enriched	 aggregates	 develop	 micro-lens	 properties.	Moreover,	 aggregated	 ROR1-enriched	 cells	 developed	 into	 micro-lenses	 albeit	within	a	shorter	timeframe	compared	to	the	purified	ROR1+	cells.	The	development	of	these	lens-like	properties	at	an	earlier	stage	might	be	attributed	to	the	presence	of	immature	LF	cells	within	the	ROR1-enriched	cell	population,	as	suggested	by	the	identification	of	β-crystallin	much	earlier	in	the	ROR1-enriched	aggregate	cultures,	(i.e.,	by	day	3).	This	suggests	that	the	40	μm	cell	strainer	step	is	sufficient	to	remove	the	majority	of	LF	cells	and	non-lens	cells,	and	in	doing	so	generates	sufficiently	pure	LEC	 populations	 for	 research	 applications.	 Notably,	 ROR1-enriched	 cells	 are	unlikely	 to	be	suitable	 for	clinical	applications	due	 to	 their	reduced	homogeneity	compared	to	purified	ROR1+	cells.		The	 use	 of	 ROR1-enriched	 cells	 makes	 generation	 of	 tens-of-thousands	 of	 light-focusing	micro-lenses	simpler	and	more	cost-effective	compared	to	purified	ROR1+	cells	 for	 laboratory-only	 investigation	 of	 cataract	 and	 for	 drug-toxicity	 assays.	However,	the	ROR1-enriched	aggregates	frequently	developed	protrusions	after	14	days	 in	 culture	 (Figure	 3.5B).	 While	 some	 minor	 bleb-like	 protrusions	 were	observed	 in	 purified	 ROR1+	micro-lenses	 produced	 in	 our	 laboratory	 (108),	 the	protrusions	 in	 ROR1-enriched	micro-lenses	 appeared	more	 frequently	 and	were	larger	than	those	in	purified	ROR1+	micro-lenses.	While	the	micro-lenses	retained	their	core	spheroidal	shape	and	defined	edge	and	the	protrusions	did	not	appear	to	be	due	to	attachment	to	the	cell	culture	plastic,	it	would	be	interesting	to	determine	whether	the	protrusions	are	due	to	an	inability	for	lens	capsule	production	to	keep	pace	with	the	growing	size	of	the	ROR1-enriched	aggregates.			
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3.4.3 Future directions using ROR1-enriched micro-lenses The	 ROR1-enriched	micro-lens	 culture	was	more	 efficient	 and	 less	 expensive	 to	produce	than	purified	ROR1+	micro-lenses.	The	MACS	process	yielded	an	average	10	 to	 20%	of	 purified	ROR1+	 cells	 from	a	 starting	ROR1-enriched	 (strained	 cell)	population	e.g.,	30	x	106	ROR1-enriched	cells	would	produce	3	to	6	x	106	purified	ROR1+	cells.	The	ROR1-enriched	cell	yield	was	 typically	80%	ROR1-positive	cells	post-filtration	 (108),	with	a	 consistent	ROR1+	 cell	morphology	after	one	week	of	culture	in	E3	medium.	Therefore,	up	to	8	times	as	many	ROR1-enriched	aggregates	could	be	produced	per	differentiation	experiment	than	purified	ROR1+	aggregates.	Furthermore,	purifying	the	ROR1+	cells	with	MACS	requires	the	use	of	an	expensive	anti-ROR1	 antibody	 as	 well	 as	 other	 MACS	 reagents	 –	 thereby	 making	 ROR1-enriched	micro-lens	production	more	cost-effective.	Overall,	efficiency	is	increased	and	 the	ROR1-enriched	aggregates	 enable	 less	 expensive	 and	 larger-scale	micro-lens	production	compared	 to	 the	same	 timeframe	using	purified	ROR1+	cells,	 yet	while	 still	 retaining	 key	 lens	 properties	 of	 light	 transmission	 and	 light	 focusing	ability.	Furthermore,	light	focusing	develops	sooner	in	ROR1-enriched	micro-lenses	further	decreasing	costs	by	reducing	growth	factor	requirements	and	time	in	micro-lens	culture	(albeit	with	the	possibility	that	the	ROR1-enriched	micro-lenses	at	this	point	in	time	may	not	be	able	to	be	cultured	as	long	before	developing	significant	protrusions).	This	suggests	that	ROR1-enriched	micro-lenses	could	be	an	effective	tool	for	large-scale	anti-cataract	drug	or	lens	toxicity	screening.	
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Chapter 4 General discussion 
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4.1 Overview of thesis outcomes: Generation of 
functional in vitro human micro-lenses for 
investigating cataract 
Cataract	 is	 a	 widespread	 issue	 and	 leading	 cause	 of	 low	 vision	 and	 blindness,	decreasing	the	quality	of	life	for	tens-of-millions	of	people	worldwide	(2).	Treatment	for	cataract	involves	removal	of	cataractous	lens	cells,	followed	by	implantation	of	an	 IOL	 to	 replace	 lens	 function.	 With	 millions	 of	 cataract	 surgeries	 performed	worldwide	each	year,	 the	overall	 cost	of	 current	surgical	 treatment	of	 cataract	 is	expensive.	 It	 also	 requires	 highly	 specialized	 equipment	 that	 can	 be	 difficult	 to	access	for	millions	of	cataract	sufferers	in	developing	countries	(7,9).	Clinical	trials	are	yet	to	identify	any	effective	drug	or	vitamin	capable	of	delaying	cataract	(161).	In	order	 to	develop	alternative	 treatments	 for	cataract,	 the	underlying	molecular	mechanisms	of	cataract	formation	must	be	identified	and	understood.	Animal	lens	models	have	assisted	in	understanding	some	aspects	of	cataract;	however,	they	do	not	 truly	 represent	 the	 human	 lens	 in	 terms	 of	 cell	 membrane	 composition	 or	protein	expression.		Previously	 published	 research	 demonstrated	 that	 heterogeneous	 cultures	containing	lens	cells	and	non-lens	cells	can	be	generated	from	human	PS	cells,	with	lens	cells	randomly	organized	in	microscopic	(90)	or	macroscopic	(91)	structures	called	 ‘lentoids’.	However,	 these	 approaches	 had	 significant	 limitations	 including	the	 inability	 to	 produce	 uniformly-sized	 lens-like	 structures	 and	 limited	 or	 no	demonstration	 of	 measurable	 light	 focusing	 or	 light	 transmission	 capability.	Furthermore,	these	‘lentoids’	were	either	abnormally	adherent	to	the	culture	plastic	or	were	lost	to	the	culture	medium	preventing	quantitative	assessment	of	key	lens	properties.	The	human	micro-lenses	produced	through	this	project	were	obtained	by	mimicking	
in	vitro	aspects	of	embryonic	teleost	lens	development.	The	micro-lenses	expressed	a	variety	of	lens-required	crystallin	proteins.	Parallel	studies	in	our	laboratory	have	shown	 that	 development	 of	 LF	 cells	 within	 the	 micro-lenses	 included	morphologically	recognizable	milestones	including	organelle	loss	and	denucleation	(108).	 These	 results	 suggest	 that	 mimicking	 non-human	 development	 patterns	might	be	a	useful	way	of	generating	other	tissue	types	from	human	PS	cells.		
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As	 noted	 in	 the	 thesis,	 there	 were	 limitations	 to	 culturing	 the	 ROR1+	 LECs	 on	chitosan	 film	 and	 with	 embedding	 the	 ROR1+	 aggregates	 in	 agarose	 (the	temperature	issues,	potential	for	contamination	and	removal	issues	from	samples	for	downstream	analyses).	Chitosan	film	remains	worthwhile	to	consider	for	future	applications	using	LECs,	perhaps	as	a	substrate	for	lens	cell	transplantation	for	in	
vivo	lens	regeneration	studies.	Additionally,	purification	of	ROR1+	cell	populations	by	MACS	requires	an	expensive	anti-ROR1	antibody	and	associated	processing	time	and	decreases	ROR1+	yield,	both	of	which	significantly	adds	to	the	cost	of	the	micro-lens	assay.	Greater	efficiency	 in	 terms	of	both	 lower	cost	and	higher	cell	number	yield	 in	 a	 given	 timeframe	 was	 achieved	 through	 use	 of	 ROR1-enriched	 cells	(obtained	via	filtration	through	a	40	µm	cell	strainer	without	MACS).	An	 attempt	 to	 further	 simplify	 the	 micro-lens	 system	 by	 assessment	 of	 several	commercially-available	 hydrogels	 as	 potential	 agarose	 replacements	 was	unsuccessful.	 This	 is	 perhaps	 unsurprising	 given	 that	 the	 field	 of	 embedding	materials	 for	 organoid	 cultures	 is	 itself	 at	 the	 edge	 of	 scientific	 knowledge	 and	technical	capabilities	(115,153,162).		Importantly,	exposure	of	the	micro-lenses	to	the	emerging	cystic	fibrosis	drug	Vx-770	(suspected	of	causing	cataract	in	cystic	fibrosis	patients)	(134)	resulted	in	loss	of	 light	 transmission	 and/or	 focusing	 ability,	 suggesting	 the	 micro-lenses	 are	suitable	for	clinically-relevant	studies	of	the	mechanism	of	cataract	formation	and	as	a	tool	for	investigating	lens	toxicity.	Moreover,	the	equipment	required	for	micro-lens	 generation	 is	 simple	 and	 readily	 available	 –	 indicating	 the	 technique	 can	be	used	in	almost	any	tissue	culture	laboratory.		
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4.2 General implications and contribution to lens 
research 
4.2.1 Investigation of risk factors The	 ability	 to	 detect	 Vx-770-induced	 cataract	 suggests	 that	 exposure	 of	 human	micro-lenses	 to	 known	 cataract	 risk	 factors	 could	 reveal	 some	 of	 the	molecular	mechanisms	 of	 cataract.	 Changes	 previously	 associated	 with	 different	 types	 of	cataractous	human	or	animal	lenses,	include	abnormal	cellular	morphologies	(e.g.,	swelling),	proliferation,	migration	and/or	differentiation;	multi-lamellar	bodies;	as	well	 as	 breakdown,	 proteolysis	 and/or	 PTM	 of	 crystallin	 proteins	 (e.g.,	 non-enzymatic	methylation	 of	 cysteine	 and	 arginine	 residues	 from	 the	metabolic	 by-product	 S-adenosyl	methionine,	 isomerization,	 cross-linking,	 oxidation,	 advanced	glycemic	 end-products,	 deamidation,	 racemization	 and	 isomerization)	(31,149,163,164).	 A	 variety	 of	 cataract	 risk	 factors	 have	 also	 been	 identified;	however,	 the	 molecular	 mechanisms	 which	 lead	 to	 any	 particular	 type	 of	cataractous	change	listed	above	is	poorly	understood.	Each	risk	factor	represents	the	potential	of	specific	compounds	or	environments	to	cause	cataract.	The	micro-lenses	can	be	exposed	to	such	risk-factors,	either	singularly	or	in	combination,	and	should	a	cataractous	change	occur	(as	it	does	with	Vx-770	treatment),	the	micro-lenses	can	be	used	to	elucidate	the	molecular	mechanism	involved.	Critically,	micro-lens	light	transmission	and	focusing	before	and	after	exposure	can	be	measured	and	used	 to	 guide	 time-point	 collection	 for	 molecular	 analyses	 (e.g.,	 genomics,	transcriptomics,	proteomics,	metabolomics	etc.).	For	example,	diabetes	is	associated	with	up	to	five-fold	increased	cataract	risk	(46).	Diabetic	 cataract	 can	 present	 as	 cortical	 and/or	 posterior	 subcapsular	 cataract	(46,165);	however,	 increased	 light	scatter	has	been	observed	 in	human	 lenses	of	diabetic	patients	 in	 the	absence	of	 visually	observable	 cataract	 (166).	A	 range	of	changes	thought	to	be	related	to	diabetes	have	been	noted	in	the	lenses	of	various	species	and	include:	osmotic	swelling,	decreased	glutathione	levels,	increased	levels	of	 oxidized	 glutathione,	 increased	 lipid	 peroxidation	 and	 PTM	 of	 crystallins,	including	 advanced	 glycation	 end-products	 (some	 of	 which	 may	 result	 in	brunescence)	 (23,29,46)	 (166-168).	Notably,	while	 an	 aldose	 reductase	 inhibitor	(Kinostat)	has	recently	been	approved	as	an	effective	treatment	of	cataract	in	dogs	
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(169),	 it	 appears	 unlikely	 to	 be	 a	 successful	 treatment	 for	 human	 cataract.	 The	micro-lens	 system	may	 therefore	provide	an	opportunity	 to	understand	whether	these	 and/or	 other	 molecular	 mechanisms	 occur	 in	 human	 lenses	 exposed	 to	diabetes-like	conditions.	Exposure	of	micro-lenses	to	a	range	of	concentrations	of	glucose	or	its	metabolic	products	(e.g.	sorbitol)	in	culture	medium	could	determine	whether,	and	at	which	concentration,	there	is	an	opacifying	effect	(166,168).	Mass	spectrometry	analysis	of	the	control	and	opacified	micro-lenses	might	then	reveal,	
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for	example,	when/how	crystallin	PTM/glycation	occurs.	Additional	 risk	 factors	 of	 cataract	 could	 be	 tested	 in	 a	 similar	 manner.	 Other	proposed	 cataract	 risk	 factors	 include	 exposure	 to	 hyperbaric	 oxygen.	 This	 is	speculated	 to	 result	 in	 glutathione	 and	 protein	 thiol	 group	 loss,	 leading	 to	insolubility	of	crystallin	and	nuclear	cataract	(170,171).	Another	risk	factor	arises	from	the	lens	being	thought	to	have	a	protective	effect	on	the	retina	by	preventing	UV	light	from	reaching	it	and	exposure	to	UVB	is	associated	with	cortical	cataract	in	rats	(38,172).	Micro-lenses	could	be	exposed	to	different	wavelengths	of	UV	light	to	determine	if	changes	occur.	Smoking	is	associated	with	cataract	(33,45).	Analysis	of	lenses	from	smokers	vs	non-smokers	has	shown	a	significant	increase	in	Al	and	V	ions	 in	 smokers;	 however,	 the	 relationship	 these	 have	 to	 cataract	 is	 unknown	(33,173)	 but	 could	 be	 investigated	 using	 the	 micro-lens	 systems.	 Significant	increases	 in	 Cd,	 Se	 and	 a	 reduction	 in	 Cu	 ions	 are	 age-related	 (33)	 and	Cd	 is	 an	inducer	 of	 oxidative	 stress	 (23).	 Exposing	 micro-lenses	 to	 these	 metal	 ions,	 at	relevant	 concentrations,	 may	 be	 utilized	 to	 investigate	 their	 relationships	 to	cataract.	An	alternative	hypothesized	mechanism	for	smoking-related	cataract	is	by	accumulation	 of	 p-benzoquinone	 (a	 compound	 associated	with	 cigarette	 smoke-related	pathogenesis)	in	the	lens	that	may	induce	αA-crystallin	aggregation	(173).	Finally,	cholesterol-lowering	statin	use	has	a	controversial	association	with	cataract	risk	 (39,174,175)	 and	 controlled	 in	 vitro	 assessment	 could	 assist	 determining	whether	there	is	an	association	between	statin	exposure	and	cataract.		Should	cataract	within	the	micro-lenses	be	induced	by	any	of	the	above	risk	factors,	then	 targeted	 analyses	 could	be	performed	 throughout	 onset	 and	progression	of	cataract	to	define	how	cataract	formation	occurs.	Once	the	molecular	mechanisms	are	elucidated	 for	cataract	 risk	 factors,	 this	could	 lead	 to	 i)	 identification	of	non-invasive	 biomarkers	 of	 diabetic	 (or	 other)	 cataract	 (that	 precede	 vision	 loss),	 ii)	identification	 of	 drug-able	 targets	 for	 diabetic	 (or	 other)	 cataract,	 and	 iii)	 a	screening	 system	 for	 identification	 of	 candidate	 anti-cataract	 drugs.	Widespread	access	to	risk	factor-specific	drugs	that	reverse	(in	some,	though	not	likely	all	cases)	or	delay	cataract	could	overcome	some	of	the	issues	of	cataract-related	impacts	on	health	and	lower	the	blindness	rate	for	people	in	developing	countries	who	do	not	have	the	access	to	cataract	surgery	that	those	in	the	developed	world	enjoy.		
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4.2.2 Toxicity screening The	exposure	of	developing	micro-lenses	to	the	drug	Vx-770	demonstrated	a	dose-dependent	 effect	 on	 cataract	 formation.	 Future	 studies	 to	 define	 the	 molecular	mechanism	of	Vx-770	induced	cataract	will	be	needed.	However,	these	Vx-770	data	also	suggest	the	micro-lens	system	can	be	used	to	investigate	other	drugs	that	can	affect	the	lens,	either	in	a	targeted	or	inadvertent	manner.	As	with	the	assessment	of	cataract	risk	factors,	micro-lenses	can	be	exposed	to	substances	to	assess	their	cataract	 potential,	 by	 measuring	 changes	 in	 micro-lens	 light	 transmission	 and	focusing.	 For	 example,	 drugs	 that	 have	 previously	 demonstrated	 formation	 of	cataract	 such	 as	 corticosteroids	 (39),	 or	 are	 associated	 with	 cataract	 like	antipsychotics,	such	as	clozapine	(176,177)	may	be	screened	using	human	micro-lenses	 to	 determine	 whether	 these	 drugs	 induce	 cataract	 in	 human	 lens	 tissue.	Importantly,	 the	 use	 of	 micro-lenses	 for	 drug	 toxicity	 screening	 would	 enable	investigation	of	drug	effects	on	human	tissue,	eliminating	any	inter-species	variance	that	may	differ	to	human	lens	tissue.	These	micro-lenses	have	greater	relevance	to	the	human	condition	than	those	from	other	species.			
4.2.3 Investigation of genetic causes of cataract The	micro-lens	 system	could	be	applied	using	ROR1+	 cells	derived	 from	disease-specific	ES	or	iPS	cells.	This	would	allow	production	of	micro-lenses	for	investigation	of	genetic	 cataract	 (32)	or	other	diseases	 that	affect	 the	 lens,	 for	example	Alport	syndrome	(74).	Mutations	can	occur	in	crystallin	genes,	lens	cytoskeletal	genes,	lens	membrane	protein	genes,	or	genes	for	lens	transcription	factors	such	as	PAX6	(178).	Production	 of	 thousands	 of	 uniform	 human	micro-lenses	 could	 transform	 future	cataract	 research	 by	 providing	 an	 investigative	 platform	 for	 research	 into	 these	genetic	sight-affecting	diseases	of	the	lens	by	producing	a	disease-in-a-dish	model	to	 both	 investigate	 the	molecular	mechanisms	 of	 the	 disease	 and	 test	 proposed	therapeutic	agents.		
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4.3 Summary 
The	establishment	of	the	ROR1	micro-lens	system	provides	numerous	opportunities	to	start	to	further	understand	lens-specific	questions.	Lens	development,	including	which	 genes	 are	 switched	 on	 and	 switched	 off	 during	 early	 lens	 development,	commencement	of	the	OFZ	in	humans	and	the	key	time	points	in	which	the	stages	occur	 can	 be	 examined.	 Risk	 factors	 for	 cataract	 can	 be	 tested	 and	 molecular	mechanisms	elucidated,	in	a	human-specific	model.	Likewise,	preventative	and/or	curative	 treatments	 of	 cataract	 can	 be	 tested.	 Drugs	 can	 be	 identified	 that	 have	human	cataract	as	side	effects,	or	alternatively	drugs	that	caused	cataract	in	animal	tissue	could	be	tested	to	see	if	they	likewise	cause	cataract	in	human	lens	tissue.	A	human	lens,	along	with	other	organoids,	can	form	a	toxicity	screening	panel	as	part	of	pre-clinical	drug	trialling.	ROR1-enriched	micro-lenses	might	be	suitable/more	cost-effective	 for	 this,	as	 they	are	higher	yielding	without	 the	need	 for	ROR1-cell	passaging	(and	thus	are	also	quicker	to	obtain),	and	they	appear	to	mature	earlier	than	purified	ROR1+	micro-lenses.	Human	ES	or	iPS	cell	generated	micro-lenses	that	express	genetic	diseases	of	 the	eye	can	now	be	 investigated	using	our	micro-lens	system.	As	a	result	of	developing	this	human	PS	cell-derived	micro-lens	system,	the	means	 to	 examine	 in	 detail	 human	 lens	 development,	 disease,	 and	 lens	 drug	screening	with	a	large	scale	reproducible	in	vitro	functional	human	lens	system,	is	now	possible.		
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Light-focusing human micro-lenses generated from pluripotent 
stem cells model lens development and drug-induced cataract in 
vitro  
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